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Crystal Engineering of Nutraceutical Cocrystals
Dalia A. Aboarayes
ABSTRACT

The work presented herein focus upon crystal engineering of nutraceutical
cocrystals. Cocrystals are considered unique solid dosage form which has many
advantages over other traditionally known solid forms. Furthermore, cocrystals have
proven to improve stability, solubility and bioavailability of Active Pharmaceutical
Ingredient (API) as shown in the case of carbamazepine and other APIs in previous
studies.
Crystal engineering is commonly used to design new solid forms based on the
bases of supramolecular chemistry. In this study, crystal engineering based on intensive
Cambridge Structural Database (CSD) analysis used to predict and design new cocrystals
of targeted nutraceuticals. Two nutraceuticals were selected for this study; resveratrol and
citric acid. The rationale behind selecting resveratrol was to improve its solubility and,
accordingly, bioavailability. On the other hand, citric acid is known as a highly soluble
and safe nutraceutical, and thus it can be used as a coformer. Five new cocrystals were
prepared and characterized using a variety of techniques that include single crystal X-ray
xi

diffraction (XRD), powder X-ray diffraction (PXRD), differential scanning calorimetry
(DSC), FT-IR, and thermo-gravimetric analysis (TGA). Most of the reported cocrystals
were obtained using different techniques; solvent slow evaporation, mechanichemical
approach, slurry, and from melt. Moreover, dissolution test has been performed on
resveratrol and two of its cocrystals, using UV-vis spectrophotometer, where the data
demonstrate that through cocrystallization with different cocrystal formers, solubility of
resveratrol could be greatly modified, and further controlled.
The polymorphism phenomenon is encountered, and accordingly addressed,
herein where four novel polymorphs were obtained during cocrystallization attempts.
Polymorphism has a significant importance in industry, in general, and in pharmaceutical
industry, in particular, due to the vast differences in physical properties of polymorphs.
Furthermore, the study of polymorphism provides valuable information essential to
understand how different crystal forms are attained.
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Chapter 1. Introduction

1.1. Crystal Engineering
The term “crystal engineering” was first introduced by Pepinsky1 in 1955, but it
was not widely employed until the pioneering works of Schmidt2 in topochemical
reactions of cinnamic acids. Later, Desiraju defined crystal engineering as “the
understanding of intermolecular interactions in the context of crystal packing and in the
utilization of such understanding in the design of new solids with desired physical and
chemical properties”.3
Thus, crystal engineering is based on the concept of forming new solids with
desired properties, using noncovalent interactions, such as hydrogen or ionic bonding.
Understanding of these interactions can be employed to obtain novel molecular entities
based on the elements of design in supramolecular chemistry.
The early beginnings of supramolecular chemistry started with works of Johannes
Diderik van der Waals in 1873. However, it was not until 1987 when the field gained a
lot of attention mainly due to the 1987 Nobel Prize in chemistry awarded to Jean-Marie
Lehn, Donald J. Cram, and Charles J. Pedersen as a result of their works in
supramolecular chemistry. Supramolecular chemistry is unique in that it relies only on
relatively weak forms of interactions. Thus, no covalent interactions are involved in
supramolecular chemistry. Therefore it is commonly known as “chemistry beyond the
1

molecules”. Of particular interest among non covalent interactions to supramolecular
chemistry are hydrogen bonding, electrostatic interactions, metal coordination, and van
der Waals interactions.
The large range of non-covalent intermolecular interactions include electrostatic
interactions (ion-ion, ion-dipole and dipole-dipole interactions), coordination bonds,
hydrogen bonds, halogen bonds, π-π stacking and Van der Waals interactions.
The concept of molecular-recognition could be considered to have emerged in
1890 when Fischer suggested "lock and key" model for enzyme-substrate interactions.
However, the definition of hydrogen bonding could be traced back to Latimer and
Rodebush in 1920.4
One important aspect of the weak intermolecular interactions involved in
supramolecular chemistry is the reversibility of the relatively weak bonding interactions
involved. This allows molecules to self-assemble and further to self-correct the overall
structure.
The term Self-assembly refers to processes in which a disordered system of preexisting components forms an organized structure or pattern as a consequence of specific,
local interactions among the components themselves, without external direction.
The molecular recognition between two molecules is accomplished through
complimentary interactions of specific functional groups in the two molecules. Such
specific complimentary interacting parts of the two molecules are usually referred to as
supramolecular synthons. The term “synthon” was introduced by Corey in 1967.5

2

A broader definition of supramolecular synthons made by Desiraju et al. where
supramolecular synthons could be visualized as “structural units within supermolecules
which can be formed and/or assembled by known or conceivable synthetic operations
involving intermolecular interactions”.6
Supramolecular synthons can then be classified to either supramolecular
homosynthons or supramolecular heterosynthons7,8. Supramolecular homosynthons are
those synthons formed between the same functionalities, while supramolecular
homosynthons are those formed between the different functionalities.
Examples of the two types are shown in Figure 1.1, where two functionalities are
complementary to each other and can be assembled through two points of recognitions to
form supramolecular homosynthons or heterosynthons.

Figure 1.1. Supramolecular homosynthons (left) and supramolecular
heterosynthons (right)9

Many case studies of supramolecular homosynthons or heterosynthons were
recently presented in research. Examples of supramolecular homosynthons can be seen in
carboxylic acid dimers10 and amide dimers.11 Supramolecular homosynthons can be seen
in carboxylic acid···amide12, carboxylic acid···Narom13, and phenol···Narom.14
3

Years ago, Feynman15 asked his famous question “What would the properties of
materials be if we could really arrange the atoms the way we want them?”. However,
advances in field of crystal engineering might be the answer to that question.
In this context, we have to note that cocrystals are amenable for design using
crystal engineering principles, which are based on supramolecular chemistry.
The research presented herein is based on exploiting the concept of donoracceptor molecular recognition of complementary functional groups to form novel
supermolecules, namely; nutraceutical cocrystals.

1.2. Cambridge Structural Database
As we discussed earlier, understanding of supramolecular interactions is the key
to crystal engineering of novel crystalline entities which could be achieved through
careful inspection of existing hydrogen bond interactions in previously reported
supermolecules, hence facilitating the supramolecular retrosynthesis.16‐18
Cambridge Structural Database (CSD), the product of Cambridge
Crystallographic Data Center (CCDC)19, is invaluable tool to study a wide collection of
reported crystal structures that enables identification of the occurrence frequency of
distinct supramolecular synthons.
CCDC began its activities in 1965, led by Dr. Olga Kennard at Cambridge
University, as a depository of crystal structures for organic and metal-organic small
molecules studied by X-ray or neutron diffraction techniques. Since its beginning, the

4

number of reported crystalline structures is exponentially increasing over the years. The
last reported number of entries is 423752, according to August 2008 update.

Figure 1.2. Growth of the CSD since 197220

Thus, CCDC is the center for archiving these crystal structures which could be
easily visualized, classified and analyzed through an integral collection of software
application impeded into the CSD program. This collection contains the following
softwares: search and information retrieval (ConQuest), structure visualization
(Mercury), numerical analysis (Vista), and database creation (PreQuest).
According to Kennard et al., about twenty years after the first release of CSD,
“The systematic analysis of large numbers of related structures is a powerful research
technique, capable of yielding results that could not be obtained by any other method”.21

5

Thus, CSD is considered as an invaluable research tool, which can be used for design and
prediction of new crystalline entities.

1.3. Cocrystals
The term cocrystal is used to describe “a long known but little-studied”22 class of
crystalline compounds.
For years, many terms have been used to describe cocrystals. Some of these terms
are: molecular compounds23, addition compounds24, organic molecular compounds25,
molecular complexes26, solid-state complexes27, and heteromolecular crystals.28
Even recently, there is still a debate around the most appropriate name for this
class of crystalline compounds.29,30
However, Dr. Zaworotko research group defines cocrystal as “a multiple
component crystal in which all components are solid under ambient conditions when in
their pure form. These components co-exist as a stoichiometric ratio of a target molecule
or ion and a neutral molecular cocrystal former(s)”.22 This definition makes clear
difference between cocrystals and salts; where in cocrystal at least one of the molecules is
neutral, while in slats both molecules are ionized. The definition also excludes hydrates
and solvates.

6

Figure 1.3. Various possible crystalline forms for an API: (a) pure API; (b)
polymorph of API; (c) clathrate hydrate/solvate of API; (d) hydrate/solvate of API;
(e) salt of API; (f ) pharmaceutical cocrystal22

As we mentioned earlier, cocrystals are a long known class of crystalline
compounds. This can be seen from works of Wohler31 in 1844, when he synthesized the
first cocrystal between benzoquinone and hydroquinone. However, the crystal structure
was determined later by Sakurai32,33 in the 1960’s.

Figure 1.4. Crystal structure of quinhydrone (CSD refcode: QUIDON)

7

The first scientific use of cocrystals was reported in work of Hoogsteen34,35, when
he studied the base pairing in the cocrystal of 9-methyladenine and 1-methylthymine, in
the contest of DNA base pairing. However, cocrystals were popularized latter by work of
Etter36.

Figure 1.5. The Hoogsteen base pairing in the cocrystal of 9-methyladenine and 1methylthymine (CSD refcode: MTHMAD)

The term “pharmaceutical cocrystals” is used to describe “A multiple component
crystal in which at least one component is molecular and a solid at room temperature (the
cocrystal former) and forms a supramolecular synthon with a molecular or ionic API”8 .
Many pharmaceutical cocrystals are currently synthesized, where they represent a novel
class of APIs, which has more advantages compared to traditionally known crystalline
forms, such as; salts, solvates, hydrates, and polymorphs.
However, pharmaceutical cocrystals have shown to improve physical properties
of APIs, such as solubility and therefore bioavailability. Two APIs37 and two of their
cocrystals were studied in animal models.
8

Carbamazepine (Tegretol®) is an anti-epileptic agent, which has many
drawbacks38,39, such as; narrow therapeutic window, autoinduction of metabolism and
dissolution-limited bioavailability, and high tendency to polymorphism. Tegretol® and
carbamazepine: saccharin cocrystals9 were tested in dog model to compare
carbamazepine bioavailability in both. As shown in figure 1.6., it is found that the
cocrystal shows higher plasma levels than that of Tegretol®.

Figure 1.6. Comparing average plasma concentrations versus time of
carbamazepine in Tegretol® and that in carbamazepine: saccharin (cocrystal 1)37

Another case study40 was performed using 2-[4-(4- chloro-2-fluorophenoxy)
phenyl] pyrimidine-4-carboxamide, a low solubility, sodium channel blocker. 2-[4-(4chloro-2-fluorophenoxy) phenyl] pyrimidine-4-carboxamide and its glutaric acid
9

cocrystal were tested in dog model. As shown in figure 1.7., it is found that the cocrystal
shows higher plasma levels than that of pure API.

Figure 1.7. Comparing average plasma concentrations versus time of 2-[4-(4chloro-2-fluorophenoxy) phenyl] pyrimidine-4-carboxamide and that in glutaric
acid cocrystal 40

It can be concluded from the above discussion that cocrystal is a promising class
of crystalline drugs, which can afford some advantages over the other traditional forms.

1.4. Crystal Forms of Drugs and Biopharmaceutical Classification System
Over the years, different routes were developed for drug administration, such as
oral, topical, and parenteral. Orally administered drugs constitute about 85% of the most
sold drugs in the USA and Europe. Moreover, orally administered drugs are available in
10

different solid or liquid dosage forms amongst which oral solid dosage forms are the most
common among other available dosage forms.
The active pharmaceutical ingredients (APIs) in solid dosage forms could either
be present as amorphous or crystalline forms. As shown in figure 1.3., there are different
possible crystalline forms for an API such as: pure API, polymorph, hydrate, solvate, salt,
or cocrystal. In all of the aforementioned cases, crystallinity of API directly affects its
physical properties, mainly solubility and dissolution rate.
The Biopharmaceutical Classification System (BCS) is a recently developed
guidance which “correlates in vitro drug product dissolution and in vivo bioavailability”.41
The BCS predicts gastrointestinal drug absorption based on dissolution and
permeability data. In this system, two parameters, namely; solubility and permeability are
used to classify oral drugs into four classes, as shown in figure 1.8.

Figure 1.8. The four classes of APIs based on BCS

11

Those two parameters are defined by FDA42 as following: a drug substance is
considered HIGHLY SOLUBLE when the highest dose strength is soluble in < 250 ml
water over a pH range of 1 to 7.5. Furthermore, a drug substance is considered HIGHLY
PERMEABLE when the extent of absorption in humans is determined to be > 90% of an
administered dose based on mass-balance or in comparison to an intravenous reference
dose.
According to this classification system, about 70% of commercially available
drugs have inherently low aqueous solubility, which therefore limit their bioavailability.
It becomes evident that drug bioavailability is mainly affected by its solubility, or more
specifically, solubility of its solid form. Therefore, as cocrystal solid forms were
demonstrated to enhance solubility of APIs, cocrystal solid forms represent interesting
targets for studies concerning enhanced bioavailability of solid APIs.

12

Chapter 2. Nutraceutical Cocrystals

2.1. Introduction
For many years, food has been used for more than its nutritional value. It is well
known that ancient civilizations used herbal products as a remedy for many diseases. The
term “pharmacognosy” was first used by Schmidt in 1811, which is derives from the
Greek words pharmakon (drug), and gnosis or "knowledge". It is defined latter by The
American Society of Pharmacognosy to describe “the study of the physical, chemical,
biochemical and biological properties of drugs, drug substances, or potential drugs or
drug substances of natural origin as well as the search for new drugs from natural
sources.43 However, formulation of a specific term to describe food or its active
ingredients, which have medicinal values, was eagerly required.
The term ‘Nutraceutical’ was coined by Dr. Stephen De Felice, founder and
chairman of Foundation of Innovation in Medicine, in 1976 to describe “food, or parts of
food, that provide medical or health benefits, including the prevention and treatment of
disease”.44
It is believed that nutraceuticals can have a rule in preventing and treating many
diseases45 ; starting from common cold, weight problems and ending with cardio vascular
diseases and even cancer.46
Nutraceuticals include many food and food products, including vitamins, soy
products, glucosamine, chondroitin, and many polyphenols and flavonoids (resveratrol,
13

ellagic acid, and quercetin). The vast majority of nutraceuticals are extracted from plant
origins; such as fruits, vegetables, roots, and rhizomes. However, many nutraceuticals are
derived from animal origins; vitamins and amino acids.
Nutraceuticals can be used as targets for cocrystal formation because many of
them have major problems with solubility and bioavailability, and cocrystal can solve
those problems, as discussed earlier in section 1.1.3. Furthermore, nutraceutical
cocrystals are patentable as they meet the criteria required for patents.47
Nutraceuticals have a big market currently and annual growth rates of
nutraceuticals are predicted to increase. This rate expected to be up to 25% for some
products.44 However, nutraceutical cocrystals can offer an opportunity for exponential
growth of nutraceuticals market.

2.2. Resveratrol
2.2.1. Introduction
Resveratrol [trans-3,5,4'-trihydroxystilbene] is a nutraceutical, extracted mainly
from skin of red grapes. It can also be obtained from other dietary sources as shown in
table 2.1.

14

Table 2.1. Different sources of resveratrol48
Source
Red wines

Trans-resveratrol
concentration
0.1–14.3 mg/L

White wines

<0.1–2.1 mg/L

Ports and sherries

<0.1 mg/L

Grapes

0.16–3.54 µg/g

Dry grape skins

24.06 µg/g

Red grape juices

0.50 mg/L

White grape juices

0.05 mg/L

Cranberry juice

0.2 mg/L

Blueberries

32 ng/g

Peanuts

0.02–1.92 µg/g

Resveratrol attracted a lot of attention when Jang et al.46 published their paper in
1997, reporting anticarcinogenic activity of resveratrol. Since that significant discover,
research on resveratrol biological activity has greatly increased, which is reflected as
exponential increase in the number of scientific publications concerning resveratrol, as
seen in figure 2.1.
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Figure 2.1. PubMed search for word ‘resveratrol’ shows exponential increase in the
number of resveratrol related publications over years48

However, medical evidences have shown that resveratrol can participate in
preventing and treating many diseases48 such as; cancer, cardiovascular diseases,
myocardial infarction, brain damage…etc. It also plays an important role in supporting
immunity and reducing stress.
There are many mechanisms48 proposed to participate in resveratrol biological
activity. Anticarcinogenic activity originates from its antioxidant properties, in addition
to its ability to inhibit cyclooxygenase (COX1 and COX2), ornithine decarboxylase, and
angiogenesis. Moreover, resveratrol activity against heart diseases originates from its
antioxidant properties, in addition to its ability to inhibit platelet aggregation and its
vasodilation effect. Furthermore, various species treated with resveratrol had shown
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lifespan extensions. Up to 70% increase in lifespan in some species was reported, but
unfortunately this effect is unknown in mammals.
However, administer of enough quantity of resveratrol is required to get those
beneficial effects. This means that resveratrol has to reach to certain blood level, i.e. it
has to be bioavailable. Unfortunately, resveratrol bioavailability is low because of two
factors. First, solubility of resveratrol is low as 0.019 mg/ml. Second, oral resveratrol
undergoes first pass effect, thus, it is predisposed to metabolism by cytochrome P450.
Hence, higher doses are required which has two main drawbacks. Toxic effects are
reported upon administering 1 or more g per kg (body weight).49 Furthermore, estimated
cost of administering enough doses is about $6,800 based on annual consumption of 2.7
kg.
Interestingly, Baur et al.48 commented on this situation as following “Therefore,
blocking the metabolism of resveratrol, developing analogues with improved
bioavailability, or finding new, more potent compounds that mimic its effects will
become increasingly important”. Hence, resveratrol is a valid target for cocrystallization
and the following sections describe how cocrystals of resveratrol were designed and the
subsequent observed effect(s) on resveratrol solubility.
However, CSD search for resveratrol reveals one crystal structure of transresveratrol, while no cocrystals were reported on CSD (August 2008 update).
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2.2.2. CSD Analysis
As we discussed earlier in section 1.2.2., CSD search can serve as a tool to predict
and design new cocrystals. Therefore, detailed CSD search conducted herein using
Conquest v. 1.10, Aug 2008 update. Filters applied to the searches to limit the results
according to the following criteria: 3D coordinates determined, R factor < 7.5%, no ions
and only organics. The alcohols were excluded from the search due to the difference
between acidity of phenols and alcohols which therefore affects their supramolecular
interactions. The results are summarized in table 2.2. were raw data indicates results in
presence of competitive hydrogen bonding groups while refined data is that in absence of
any competitive groups.

Table 2.2. CSD statistics for phenols
Functional group

Raw data

Refined data

Bond distance
range (Å)

mean σ (Å)

OH···OH

1045/7069
(14.8%)

129/216 (59.7%)

2.504-3.069

2.817(3)

Primary amide
OH···CONH2
OH···NH2CO

26/81(32%)
29/81(35.8%)

6/6 (100%) 6/6
(100%)

2.607-3.497
2.765-3.162

2.944(57)
3.018(13)

secondary amide

24/52 (46.1%)

10/10 (100%)

2.603-2.767

2.683(11)

OH···CO OH···NH

23/52 (44.2%)

7/10 (70%)

2.892-3.489

3.271(47)

OH···CO

619/1653 (37.5%)

162/247 (65.6%)

2.525-3.098

2.776(4)

OH···Narom

338/595 (56.8%)

107/130 (82.3%)

2.515-3.114

2.750(3)

CSD Conquest v. 1.10, Aug 2008 update, organics only, 3D coordinates, R<7.5%, no ions
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CSD search reveals 7069 entries with phenolic OH. In presence of competitive
groups, 1045 (14.8%) entries exhibit OH···OH supramolecular homosynthon. The
percentage increases to 59.7% in absence of competitive functional groups. The
histogram for bond distance range is shown in figure 2.2. and it reveals bond distance
range of 2.504-3.069 Å (mean = 2.817(3) Å).

Figure 2.2. Histogram for OH···OH homosynthon

Furthermore, several CSD searches were carried out to investigate supramolecular
heterosynthons. CSD search for structures with both phenolic OH and primary amide
reveals 81 entries. In presence of competitive groups, 26 (32%) entries exhibit
OH···CONH2 supramolecular heterosynthons while 29 (35.8%) entries exhibit
OH···NH2CO supramolecular heterosynthons. The percentage increases to 100%, for both
OH···CONH2 and OH···NH2CO, in absence of competitive functional groups. The
histogram for bond distance range is shown in figure 2.3. and it reveals bond distance
range of 2.607-3.497Å (mean = 2.944(57) Å) and 2.765-3.162 Å (mean = 3.018(13) Å),
for OH···CONH2 and OH···NH2CO, respectively.
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Figure 2.3. Histogram for OH···CO primary amide (left) and that for OH···NH2
primary amide (right)

Another CSD search reveals 52 entries with both phenolic OH and secondary
amide. In presence of competitive groups, 24 (46.1%) entries exhibit OH···CONH
supramolecular heterosynthons while 23 (44.2%) entries exhibit OH···NHCO
supramolecular heterosynthons. The percentages increase to 100% for OH···CONH and
70% for OH···NHCO, in absence of competitive functional groups. The histogram for
bond distance range is shown in figure 2.4. and it reveals bond distance range of 2.6032.767 Å (mean = 2.683(11) Å) and 2.892-3.489 Å (mean = 3.271(47) Å), for
OH···CONH and OH···NHCO, respectively.
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Figure 2.4. Histogram for OH···CO secondary amide (left) and that for OH···NH
secondary amide (right)

To investigate supramolecular heterosynthons between phenolic OH and aldehyde
or ketone, carbonyl group is used as a representative for the two later groups. CSD search
reveals 1653entries with both phenolic OH and carbonyl group. In presence of
competitive groups, 619 (37.5%) entries exhibit OH···CO supramolecular heterosynthons.
The percentages increase to 65.6% in absence of competitive functional groups. The
histogram for bond distance range is shown in figure 2.5. and it reveals bond distance
range of 2.525-3.098 Å (mean = 2.776(4) Å).

Figure 2.5. Histogram for OH···CO
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Another CSD search reveals 595 entries with both phenolic OH and aromatic
nitrogen, Narom. In presence of competitive groups, 338 (56.8%) entries exhibit
OH···Narom supramolecular heterosynthons. The percentages increase to 82.3% in absence
of competitive functional groups. The histogram for bond distance range is shown in
figure 2.6. and it reveals bond distance range of 2.515-3.114 Å (mean = 2.750(3) Å).

Figure 2.6. Histogram for OH···Narom

2.2.3. Experimental
All the chemicals used during the preparation were obtained from commercial
sources and used as received. All crystallization experiments were conducted in an
unmodified atmosphere and the solvents were distilled prior to use.

2.2.3.1. Resveratrol-caprolactam cocrystals (DA182901 and DA182902)
22.8mg (0.100 mmol) of resveratrol and 22.6mg (0.200 mmol) of ɛ-caprolactam
were dissolved in 5ml of hot acetone. The solution was allowed to slowly evaporate at
room temperature and pale yellow crystals of DA182901 were harvested after one day
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(yield = 36.2mg, 0.0796 mmol, 79.7%).
DA182901 can also be obtained through solvent drop grinding of transresveratrol (22.8mg, 0.100 mmol), ɛ-caprolactam (22.6mg, 0.200 mmol) and acetone
(20µl) for 5 min in an agate pestle and mortar. DA182901 can also be obtained from
slurry of 1:2 of trans-resveratrol and ɛ-caprolactam in acetone. (Melting point = 107oC).
After few weeks of first report of DA182901, crystals of DA182901 were
transformed to DA182902 crystals (Melting point = 113oC). However, DA182901 were
not obtained after appearance of DA182902 crystals.

Figure 2.7. Single crystal of resveratrol-caprolactam cocrystal (DA1829)

2.2.3.2. Resveratrol-flavone cocrystals (RESVONE 01 and RESVONE02)
11.4 mg (0.050 mmol) of trans-resveratrol and 22.2 mg (0.100 mmol) of flavone
were dissolved in 1ml of acetone to result in a clear solution. The solution was allowed to
slowly evaporate at room temperature resulting in yellow glassy material and a white
precipitate. Re-dissolving in hot 1ml of ethyl acetate then allowing the solvent to slowly
evaporate at room temperature resulted in pale yellow crystals of RESVONE01 that were
harvested after one day (yield = 22.5mg, 0.0334 mmol, 67%).
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RESVONE01 can also be obtained from slurry of trans-resveratrol (114 mg, 0.
500 mmol), flavone (222mg, 1.00 mmol)) and 2 ml acetone, which was stirred for five
hours then filtered. The filtrate was allowed to slowly evaporate at room temperature to
obtain crystals of RESVONE01.
RESVONE01can also be obtained by grinding of trans-resveratrol (11.4mg, 0.050
mmol) and flavone (22.2mg, 0.100 mmol) for 5 min in an agate pestle and mortar using
either 20µl of acetone, ethyl acetate or equal mixture of acetone and ethyl acetate.
(Melting point = 160oC).
Crystals of RESVONE02 were reported during preparation of RESVONE01
crystals. RESVONE02 crystals appeared once and then disappeared. Efforts to prepare
RESVONE02 resulted always in obtaining RESVONE 01 crystals

Figure 2.8. Single crystals of resveratrol-flavone cocrystal (RESVONE01)

2.2.3.3. Resveratrol and 4,4'-dipyridyl cocrystal(DA4)
22.8 mg (0.100 mmol) of resveratrol and 15.6 mg (0.100 mmol) of 4,4'-dipyridyl
were dissolved in 6ml of acetone by heating on a hotplate until a clear solution was
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obtained. The solution was allowed to slowly evaporate at room temperature and pale
yellow crystals of DA4 were harvested after one day (yield = 34mg, 0.0368, 88.5%).
DA4 can also be obtained through solvent drop grinding of 22.8 mg (0.100
mmol) of resveratrol, 15.6mg (0.100 mmol) of 4,4'-dipyridyl and acetone (10ul) for 10
min in an agate pestle and mortar. DA4 can also be obtained from slurry of resveratrol
(228mg, 1 mmol), 4,4'-dipyridyl (156mg, 1 mmol) and 4 ml acetone. (Melting point =
236 oC).

Figure 2.9. Single crystals of resveratrol and 4,4'-dipyridyl (DA4)

2.2.4. Results and discussion
2.2.4.1. Resveratrol-caprolactam cocrystals (DA182901 and DA182902)
OHb

B
OHc

A
OHa

Figure 2.10. The molecular structure of trans-resveratrol molecule shows labeled
rings and phenolic OH groups
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The single crystal x-ray analysis of DA1829 crystals reveals that it forms a 1:2
ratio cocrystal between trans-resveratrol and ɛ-caprolactam. Trans-resveratrol molecules
form head-to-tail chains through phenolic supramolecular homosynthons, OH···OH (D =
2.7905(12) Å). Each trans-resveratrol molecule is hydrogen bonded to three molecules of
ɛ-caprolactam through the following synthons: OHa···CO, OHb···CO, and OHc···NH (D =
2.5725(13), 2.6587(12), and 2.9299(14) Å respectively). One of the ɛ-caprolactam
molecules is further linked to another ɛ-caprolactam molecule to form a centrosymmetric
dimer, NH···CO (D = 2.8871(14) Å). The whole structures shows extended sheets of
trans-resveratrol and ɛ-caprolactam molecules. Those sheets are further extended to form
three dimensional structures.

Figure 2.11. Comparing the asymmetric unit of two polymorphs of 1:2 cocrystal of
trans-resveratrol and

-caprolactam, DA182901 (left) with that of DA182902 (right)

The single crystal x-ray analysis of DA182902 crystals reveals that it forms a 1:2
ratio cocrystal between trans-resveratrol and ɛ-caprolactam. Each trans-resveratrol
molecule is hydrogen bonded to four molecules of ɛ-caprolactam through the following
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synthons: OHa···CO, OHa···NH, OHb···CO, OHc···NH and OHc···CO (D = 2.690(12),
2.992(12), 2.705(14), 2.896(13), and 2.639(14) Å). The whole structures shows extended
sheets of trans-resveratrol and ɛ-caprolactam molecules. Those sheets are further
extended to form three dimensional structures.

Figure 2.12. Comparison of hydrogen bonding in DA182901 (up) and DA182902
(down)

Comparing the two polymorphs, DA182901 shows both supramolecular
homosynthons and supramolecular heterosynthons in the same crystal structure. On the
other hand, DA182902 shows only supramolecular heterosynthons in its crystal structure.
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Based on CSD search for phenols, OH···OH supramolecular homosynthons were
observed in 14.78% of the entries in presence of other competitive groups. On the other
hand, in absence of competitive groups, OH···CONH supramolecular heterosynthons
were reported in 100% of the entries, while OH···NHCO were reported in 70% of the
entries. Thus, crystal structure of DA182902 was more expected than that of DA182902.
All observed hydrogen bonding distances are within the accepted range based on CSD
search discussed in section 2.2.2.
There is also a major difference between the dihedral angles of the two aromatic
ring planes of resveratrol. That dihedral angle is 15.41° in DA182901 while it becomes
smaller as 5.89° in DA182902. The latter value is close to that angle in DALGON which
is 5.33°.
This case of polymorphism originates from flexibility of trans-resveratrol
molecule, thus, it can be considered as conformational polymorphism. At the same time
the two polymorphs adopt different packing, so, it can also be considered as packing
polymorphism.
Efforts to reproduce DA182901 crystals resulted in obtaining crystals of
DA182902 which indicates that DA182902 is the most stable form. The difficulty to
obtain DA182901 crystals may result from contamination by DA182902 seeds. This
indicates that DA182902 is the thermodynamically favored while DA182901 is the
kinetically more favored form.
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2.2.4.2. Resveratrol-flavone cocrystals (RESVONE 01 and RESVONE 02)
OHb

O

B
A

OHc

O

OHa

Figure 2.13. Molecular structures of trans-resveratrol molecule (left), and that of
flavone (right)
The single crystal x-ray analysis of RESVONE01 crystals reveals a 1:2 ratio
cocrystal between trans-resveratrol and flavone, respectively. The structure exhibit
molecules of trans-resveratrol bridged through hydrogen bonding to flavone molecules,
whereas flavone molecules aligned perpendicular to trans-resveratrol molecules. The
hydrogen bond interactions between trans-resveratrol and flavone molecules occur
through the phenolic OH and CO of resveratrol and flavone, respectively, with OH···CO
distances of 2.715(11), 2.721(12), and 2.759(12) Å. The structure also contains two
flavone molecules involved in π- π interaction with a head-to-tail arrangement, centroidto-centroid distance of 3.680 Å. Weak hydrogen bonding between phenolic OH and CH
of trans-resveratrol molecules are present, OH···CH (D = 3.413 and 3.498 Å).

Figure 2.14. Comparing the asymmetric unit of two polymorphs of 1:2 cocrystal of
trans-resveratrol and flavone, RESVONE01 (left) with that of RESVONE02 (right)
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The single crystal x-ray analysis of RESVONE02 crystals reveals a 1:2 ratio
cocrystal between trans-resveratrol and flavone, respectively. The hydrogen bond
interactions between trans-resveratrol and flavone molecules occur through the phenolic
OH and CO of resveratrol and flavone, respectively, with OH···CO distances of 2.773(6),
2.737(4), and 2.736(4) Å. The structure also contains two flavone molecules involved in
π- π stacking with a head-to-tail arrangement, centroid-to-centroid distance of 3.675 Å.
The overall structures shows alternating molecules of trans-resveratrol and flavone
whereas flavone molecules aligned perpendicular to trans-resveratrol molecules.

Figure 2.15. Comparison of hydrogen bonding in RESVONE01 (left) and
RESVONE02 (right)

Figure 2.16. Comparison of hydrogen bonding pattern in RESVONE01 (left) and
RESVONE02 (right)
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It is observed that in both structures, oxygen ether did not involve in any
hydrogen bonding interactions. Furthermore, phenolic supramolecular homosynthon did
not observe in any of the two polymorphs. Thus, supramolecular heterosynthons were
dominant over supramolecular homosynthons. This is consistent with CSD search for
phenols which reveals that in absence of competitive groups, OH···CO supramolecular
heterosynthons are observed in 65.59% of entries. Furthermore, OH···OH
supramolecular homosynthons were not expected as their occurrence reported only in
14.78% entries, in presence of competitive groups. Moreover, all observed hydrogen
bonding distances are within the accepted range based on CSD search discussed in
section 2.2.2. Thus, the structures reported herein are considered to be expected based on
CSD search.
This case of polymorphism can be explained in terms of packing and variations in
dihedral angles because trans- resveratrol and flavone are both flexible molecules.
The dihedral angle of the two aromatic ring planes of trans- resveratrol is 7.46° in
RESVONE01 while it becomes larger as 12.49° in RESVONE02. The earlier value is
close to that angle in DALGON which is 5.33°.
On the other hand, the dihedral angles between chromone and phenyl rings, in
flavone molecules, are also different in the two polymorphs. The angles values are 6.65°
and 3.79° in RESVONE01. On RESVONE02, the values are 9.42° and 13.17°.
Since this case of polymorphism originates from flexibility of trans- resveratrol
and flavone molecules, thus, it can be considered as conformational polymorphism. At

31

the same time the two polymorphs adopt different packing, so, it can also be considered
as packing polymorphism.
Efforts to reproduce RESVONE02 crystals resulted in obtaining crystals of
RESVONE01 which indicates that RESVONE01 is the most stable form. The difficulty
to obtain RESVONE02 crystals may result from contamination by RESVONE01 seeds.
This indicates that RESVONE01 is the thermodynamically favored while RESVONE02
is the kinetically more favored form.

2.2.4.3. Resveratrol and 4, 4’-dipyridyl cocrystal (DA4)
The single crystal x-ray analysis of DA4 crystals reveal that it forms a 2:3 ratio
cocrystal between resveratrol and 4,4'-dipyridyl.

Figure 2.17. The asymmetric unit of DA4

Two sets of tetrameric units are formed between trans-resveratrol and 4,4'dipyridyl molecules forming OH···Narom supramolecular heterosynthons through the two
phenolic OH groups of resveratrol located at meta position to each other and aromatic
nitrogen atom of 4,4'-dipyridyl. These tetrameric units are linked through OH···Narom
hydrogen bond formed between the third phenolic OH group of resveratrol and aromatic
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nitrogen atom of 4,4'-dipyridyl forming spiral tapes. The hydrogen bond distances
between the phenolic OH···aromatic nitrogen (OH···Narom) are as following: 2.804(5),
2.707(4), 2.850(5), 2.762(5), 2.725(5), and 2.726(5) Å.

Figure 2.18. Two sets of tetrameric units in DA4

Figure 2.19. Spiral tapes of DA4

It is observed that phenolic supramolecular homosynthons did not observe in
DA4. Thus, supramolecular heterosynthons were dominant over supramolecular
homosynthons. This is consistent with CSD search for phenols which reveals that in
absence of competitive groups, OH···Narom supramolecular heterosynthons are observed
in 82.31% of entries. Furthermore, OH···OH supramolecular homosynthons were not
expected as their occurrence reported only in 14.78% entries, in presence of competitive
33

groups. Moreover, all observed hydrogen bonding distances are within the accepted range
based on CSD search discussed in section 2.2.2. Thus, DA4 crystal structure is
considered to be expected based on CSD search.
Furthermore, the observed structure was expected based on Aoyama et al.50 and
MacGillivray et al.51-53 work on [2+2] photodimerization in case of resorcinol and 4,4´bpe derivatives, were OH···Narom supramolecular heterosynthons were occasionally
observed.

Figure 2.20. [2+2] photodimerization of 2 (4,4´-bpe) and 2(resorcinol)51
Based on Schmidt work, parallel olefins separated by < 4.2 Å should be used for
photodimerization.54 However, 4,4'-dipyridyl molecules in DA4 are parallel and separated
by 3.916Å and 3.764Å.
In fact, there are no olefins in the case presented herein. But the ability of this
cocrystal to exhibit this topology and distances predict that cocrystallization of transresveratrol with other derivatives of 4,4'-dipyridyl may result in cocrystals which become
suitable for photodimerization.
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2.2.5. Dissolution test
As discussed earlier in section 1.4., biopharmaceutical classification system
(BCS) considers aqueous solubility as one of the factors that directly affect drug
bioavailability. However, the vast majority of APIs tend to have low aqueous solubility,
therefore, improving their solubility is necessary to improve their bioavailabilities.
Aqueous solubility could be enhanced by particle size reduction, lyophilization,
additives, and forming new crystalline forms such as new polymorphs, salts, or
cocrystals.
Several studies of pharmaceutical cocrystals demonstrated that solubility of a
particular API could be controlled via cocrystallization.55,56 Fluoxetine hydrochloride
(Prozac®), a commonly used antidepressant, has been studied in this context. Aqueous
dissolution rate of three cocrystals of fluoxetine HCl were determined and compared to
that of fluoxetine HCl. As shown in figure 2.24., alteration of dissolution rate of
fluoxetine HCl has been observed. Fluoxetine HCl: succinic acid cocrystal exhibits 2-fold
increase in dissolution rate, while the rate decreases to the half in case of fluoxetine HCl:
benzoic acid cocrystal. In addition, a slight increase in dissolution rate has been reported
in case of fluoxetine HCl: fumaric acid cocrystal. Thus, it becomes evident that
dissolution rate of an API can be modified, and further controlled, by cocrystallization.
Furthermore, this case could be considered as an obvious illustration of how cocrystals
can afford higher aqueous dissolution rates comparing to salts.
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Figure 2.21. Dissolution profiles of Fluoxetine HCl and its cocrystals55

Another case study on dissolution rate was performed on itraconazole
(Sporanox®), an antifungal drug with low aqueous solubility, which is marketed in the
amorphous form. Figure 2.25. shows the dissolution profiles of itraconazole and four of
its cocrystals, which reveals up to 20-fold increase of itraconazole dissolution rate, while
cocrystallized with organic acids, compared to that of amorphous itraconazole.

Figure 2.22. Dissolution profiles of itraconazole and its cocrystals (itraconazole
presented by white)56
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However, no reports exist in current literature concerning dissolution studies of
nutraceutical cocrystals, in general, and trans-resveratrol, in particular. Therefore, we
report herein a dissolution study of trans-resveratrol and two of its cocrystals. UV-vis
spectrophotometer was employed in this study due to presence of two aromatic rings in
trans-resveratrol which represent the chromophores.
Since dissolution rate can greatly be affected by particle size, all samples were
sieved using ASTM sieve in order to keep particle sizes between 53µm-75µm.
Because of the inherent low solubility of resveratrol in water, aqueous medium
was not suitable to conduct the intended investigation. Moreover, 25% ethanol: water
solvent system resulted in poor dissolution of the solids. In a 50% aqueous ethanol (v/v),
satisfactory dissolution profiles were obtained and thus this solvent system was employed
in this study.
Since both trans-resveratrol and flavone have closely similar conjugated systems,
i.e. chromophores, there was an interference between their UV absorption spectra.
However, that interference was avoided by measuring absorbance at 345 nm where
absorbance of trans-resveratrol only could be recorded in this region.
Calibration plot for trans-resveratrol was created using a range of known
concentrations of trans-resveratrol and recording the corresponding absorbance at 345
nm. Furthermore, little shift in absorbance profile of trans-resveratrol was detected in
case of its cocrystals, which could be explained as a result of interactions between transresveratrol and its coformers. Thus, additional calibration plots were created for each
cocrystal where the concentration of resveratrol in each case is known based on the
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composition in the single crystal structure. Trans-resveratrol constitutes 50.2 wt% and
34.0 wt% in the case of trans-resveratrol-caprolactam (DA182902) and trans-resveratrolflavone (RESVON01) cocrystals, respectively.
All the experiments were carried out at 296 K, and three sets of each sample were
performed to keep the accuracy.
Using stir bars, the samples were stirred at 125 rpm for four hours. Fixed amounts
of the aliquot were drawn at various time intervals, and filtered using 0.25 mm syringe
filters equipped with 0.45 µm nylon membranes. Proper dilutions were performed to
obtain acceptable absorption values, and then UV absorbance was recorded. Finally,
concentration of trans-resveratrol was calculated using calibration plots and dilution
factors. Finally, dissolution profiles were created using time versus concentration of
trans-resveratrol, as shown in figure 2.26.

Resveratrol Dissolution
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Figure 2.23. Dissolution profiles of trans-resveratrol and its cocrystals
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The dissolution profiles indicate a 4-fold increase of trans-resveratrol dissolution
rate in case of trans-resveratrol: caprolactam cocrystal (DA182902). On the other hand,
trans-resveratrol: flavone cocrystal (RESVONE01) has a low dissolution rate.
This can be explained in terms of relative solubility57 and trends in melting points.
Relative solubility could be calculated as a ratio of solubility of the cocrystal former to
that of the drug in the same solvent system.
It is believed that substance with high melting point has strong self interactions,
and therefore, it will not dissociate easily, and in other words, it will not dissolve easily.
The opposite is true for low melting point substance.
It is found that relative solubility of trans-resveratrol: caprolactam cocrystal is
higher than that of trans-resveratrol: flavone cocrystal. This is in agreement with trends
in melting points, trans-resveratrol: flavone cocrystal is higher than that of transresveratrol: caprolactam cocrystal. These results are in agreement with RodriguezHornedo et al.57
In summary, cocrystallization could be used to control solubility of nutraceuticals,
either by increasing or decreasing their solubilitis.

2.2.6. Conclusion
The choice of trans-resveratrol as a target for cocrystallization attempts conducted
in this study is justified due to the rapidly growing interest in current literature
establishing desirable pharmacological properties of resveratrol and, equally important,
the known poor solubility and bioavailability of resveratrol. The principles and concepts
of crystal engineering were implemented in developing a suitable strategy to produce
39

cocrystals of resveratrol. Through a statistical analysis of CSD, phenols, in general, were
found to be able to participate in hydrogen bond interactions forming supramolecular
heterosynthons with a variety of functional groups including secondary amide, aromatic
nitrogen, and carbonyl. Therefore, molecules that contain these functionalities were
employed as cocrystal formers in the design strategy for resveratrol cocrystallization.
Three cocrystals of trans-resveratrol are presented herein and it is found that they can be
obtained by different cocrystallization techniques.
Interestingly, two cases of polymorphism in cocrystals are reported herein. CSD
search for polymorphic cocrystals shows only 40 cases, which represents 1.9% of the
total number of cocrystals available on CSD (August 2008 update).
Moreover, dissolution test was performed on resveratrol and two of its cocrystals,
using UV-vis spectrophotometer, where the data demonstrate that through
cocrystallization with different cocrystal formers, dissolution rate of resveratrol could be
greatly modified, and further controlled.
In conclusion, cocrystals are amenable to design and prediction using basics of
crystal engineering and supramolecular chemistry, where CSD is considered as
invaluable tool in this context. Overall, nutraceutical cocrystals represent viable and
readily accessible crystalline forms to enhance, and further control, the solubility of
nutraceuticals.
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2.3. Citric accid
2.3.1. Introduction
Citric acid [2-hyddroxy-1,2,3-ppropanetricaarboxylic acid] is a nutraceutical, exiists
inn a variety off fruits. How
wever, it is mainly
m
extraccted from cittrus fruits as it constitutees
abbout 8% of their
t
dry weiight.58

Figu
ure 2.24. Moolecular stru
ucture of cittric acid

use of its anttioxidant prooperties, citriic acid is widdely used as a natural foood
Becau
prreservative. It also playss an importannt role in bioochemistry as
a an intermeediate in citrric
accid cycle. Ho
owever, citriic acid has many
m
uses annd applicatioons in industtry, in generaal,
annd in pharmaceutical inddustry, in paarticular since it has a parrticular valuue as an
exxcipient.59 Itt is widely used
u
as flavoring and stabbilizing agennt in many pharmaceutic
p
cal
prreparations. The charactteristic effervvescence of antacids is a result of coombining
bicarbonates or carbonatees with citricc acid. Moreover, citric acid
a is used in
i many cases to
foorm salts of APIs.
D
Adminnistration (FD
DA) consider citric acid as a
Furtheermore, U.S. Food and Drug
saafe substance; therefore,, it is a membber of EAFU
US list (Everrything Addeed to Food inn the
U
United
Statess).60 It also haas high LD550 (3000 mg//kg in rat). Inn addition too its safety, citric
c
accid is consid
dered to be highly
h
solublle in water (11330mg/ml).
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Thus, citric acid is safe, highly soluble, and abundant in low cost, therefore, it
could be considered as a valid cocrystal former.
However, CSD search for citric acid reveals a two polymorphs of unhydrous citric
acid and a crystal structure of citric acid monohydrate (CSD refcodes: CITRAC10,
CITRAC11 and CITARC, respectively). Four crystal structures were reported as
cocrystals formed between citric acid and the following cocrystal formers: 2,5-bis(4Pyridyl)-1,3,4-oxadiazole, betaine, theophylline monohydrate, and caffeine (CSD
refcodes: MEBRUH, XOBHIF, KIGKAN, and KIGKER). (CSD August 2008 update).

2.3.2. CSD analysis
As we discussed earlier in section 1.2.2., CSD search can serve as a tool to predict
and design new cocrystals. Therefore, detailed CSD search conducted herein using
Conquest v. 1.10. Filters applied to the searches to limit the results according to the
following criteria: 3D coordinates determined, R factor < 7.5%, no ions and only
organics. The search included acids and alcohols because they are the targeted functional
groups in citric acid. Interestingly, both acids and alcohols can serve as hydrogen bond
donors or acceptors. Phenols were excluded from the search for alcohols due to the
difference between acidity of phenols and alcohols which therefore affects their
supramolecular interactions. The results are summarized in tables 2.3. and 2.4. were raw
data indicates results in presence of competitive hydrogen bonding groups while refined
data is that in absence of any competitive groups.
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2.3.2.1. CSD statistics for acids
Citric acid molecule contains three carboxylic acid groups. Those groups can
serve as hydrogen bond donors, OH, and acceptors, CO. The results of CSD search for
carboxylic acids are summarized in table 2.3. and it is based on 5690 entries.

Table 2.3. CSD statistics for acids
Functional
group
COOH···Narom
COOH···ClCOOH···P=O
COOH···OH

Raw data

Refined data

Bond distance (Å)

mean σ (Å)

457/607 (75.29%)
171/267 (64.04%)
68/122 (56%)
OH···COOH
523/1176 (44.47%)
OH···HOOC
501/1176
(42.60%)

119/126 (94.44%)
51/51 (100%)
17/17 (100%)

2.510-2.827
2.772-3.238
2.417-2.852

2.652(2)
3.001(4)
2.579(6)

173/230 (75.22%)
186/230 (80.87%)

2.607-3.000 2.4142.989

2.790(3)
2.655(3)

2.583(5)
2.957(9)

COOH···CONH2

78/177 (44.07%)

10/19 (52.63%)

COOH···CONH2
(2.501-2.713)
CONH2···COOH
(2.809-3.247)

COOH···COOH

Dimers
1785/5690(31.37%)
Catemers
156/5690 (2.74%)

Dimers
384 /474 (81%)
Catemers
35/474 (7.4%)

2.536-2.983

2.649(1)

COOH···CO

147/597 (24.62%)

67/178 (37.64%)

2.451-2.863

2.689(5)

CSD Conquest v. 1.10, Jan 2008 update, organics only, 3D coordinates, R<=7.5%, no ions

CSD search reveals 607 entries with both COOH and Narom. In presence of
competitive groups, 457 (75.29%) entries exhibit COOH···Narom supramolecular
heterosynthons. The percentage increases to 94.44% in absence of competitive functional
groups. The histogram for bond distance range is shown in figure 2.28. and it reveals
bond distance range of 2.510-2.827Å (mean = 2.652(2) Å).
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Figure 2.25. Histogram for COOH···Narom

–

Another CSD search for structures contain both COOH and Cl reveals 267
–

entries. In presence of competitive groups, 171 (64.04%) entries exhibit COOH··· Cl
supramolecular heterosynthons. The percentage increases to 100% in absence of

competitive functional groups. The histogram for bond distance range is shown in figure
2.29. and it reveals bond distance range of 2.772-3.238Å (mean = 3.001(4) Å).

Figure 2.26. Histogram for COOH···Cl–

44

Another CSD search for structures with both COOH and P=O reveals 122 entries.
In presence of competitive groups, 68 (56%) entries exhibit COOH···P=O supramolecular
heterosynthons. The percentage increases to 100% in absence of competitive functional
groups. The histogram for bond distance range is shown in figure 2.30. and it reveals
bond distance range of 2.417-2.852 Å (mean = 2.579(6) Å).

Figure 2.27. Histogram for COOH···P=O
Another CSD search for structures with both COOH and alcoholic OH reveals
1176 entries. In presence of competitive groups, 523 (44.47%) entries exhibit
OH···COOH supramolecular heterosynthons while 501 (42.60%) entries exhibit
OH···HOOC supramolecular heterosynthons. In absence of competitive functional
groups, the percentage increases to 75.22% and 80.87%, for OH···COOH and
OH···HOOC, respectively. The histogram for bond distance range is shown in figure
2.31. and it reveals bond distance range of 2.607-3.000Å (mean = 2.790(3) Å) and 2.414
Å-2.989 Å (mean = 2.655(3) Å), for OH···COOH and OH···HOOC, respectively.
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Figure 2.28. Histogram for OH···COOH (left) and that for OH···HOOC (right)

Another CSD search for structures with both COOH and primary amide reveals
177 entries. In presence of competitive groups, 78 (44.07%) entries exhibit
COOH···CONH2 supramolecular heterosynthons. The percentage increases to 52.63%, in
absence of competitive functional groups. The histogram for bond distance range is
shown in figure 2.32. and it reveals bond distance range of 2.501-2.713 Å (mean =
2.583(5) Å) and 2.809-3.247 Å (mean = 2.957(9) Å), for COOH···CONH2 and
CONH2···COOH , respectively.

Figure 2.29. Histogram for COOH···CONH2 (left) and CONH2···COOH (right)
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For search of carboxylic acid supramolecular homosynthons, CSD search reveals
5690 entries with carboxylic acid. In presence of competitive groups, 1784 (31.35%)
entries exhibit acid dimers while156 (2.74%) entries exhibit acid catemers. In absence of
competitive functional groups, the percentages increase to 81% and 7.4%, for acid dimers
and catemers, respectively. The histogram for bond distance range is shown in figure
2.33. and it reveals bond distance range of 2.536-2.983 Å (mean = 2.649(1) Å).

Figure 2.30. Histograms for carboxylic acid dimers

To investigate supramolecular heterosynthons between carboxylic acids and
aldehydes or ketones, carbonyl group is used as a representative for the two later groups.
CSD search reveals 597 entries with both COOH and CO. In presence of competitive
groups, 147 (24.62%) entries exhibit COOH···CO supramolecular heterosynthons. The
percentage increases to 37.64% in absence of competitive functional groups. The
histogram for bond distance range is shown in figure 2.34. and it reveals bond distance
range of 2.451-2.863 Å (mean = 2.689(5) Å).
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Figure 2.31. Histogram for COOH···CO

2.3.2.2. CSD statistics for alcohols
Citric acid molecule contains one alcoholic OH. This group can serve as hydrogen
bond donor and acceptor. The results of CSD search for carboxylic acids are summarized
in table 2.4. and it is based on 25035 entries. Phenols were excluded from this search
because the difference between acidity of alcohols and phenols, as discussed earlier.

Table 2.4. CSD statistics for alcohols
Functional group

Raw data

Refined data

-

OH···Cl

Bond distance
(Å)
2.853-3.496

mean σ (Å)

389/529 (75.53%)
0
3.116(4)
144/252 (57.14%)
50/54 (92.59%)
OH···CONH2
OH···CONH2
2.607-2.997
2.759(6)
OH···CONH2
2.737-3.198
2.990(6)
141/252 (55.95%)
49/54 (90.74%)
OH···NH2CO
OH···NH2CO
OH···P=O
202/368 (54.89%)
32/48 (66.67%)
2.429-2.899
2.714(4)
OH···Narom
457/930 (49.14%)
70/102 (68.63%)
2.590-3.099
2.821(4)
COOH···COOH
173/230 (75.22%)
523/1176 (44.47%)
2.607-3.000
2.790(3)
OH···COOH
186/230 (80.87%)
COOH···HOOC
2.414-2.989
2.655(3)
501/1176 (42.60%)
OH···CO
1694/3886 (43.59%)
552/851 (64.86%)
2.413-3.098
2.825(2)
OH···OH
5184/18475 (28.06%)
824/1055 (78.10%)
2.510-3.070
2.797(5)
CSD Conquest v. 1.10, Jan 2008 update, organics only, 3D coordinates, R<=7.5%, no ions
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–

CSD search for structures contain both OH and Cl reveals 529 entries. In presence
–

of competitive groups, 389 (75.53%) entries exhibit OH···Cl supramolecular
heterosynthons. Interestingly, in absence of competitive functional groups, no entries
–

with both OH and Cl were found. The histogram for bond distance range is shown in
figure 2.35. and it reveals bond distance range of 2.853-3.496Å (mean = 3.116(4) Å).

Figure 2.32. Histogram for OH···Cl–

Another CSD search for structures with both OH and primary amide reveals 252
entries. In presence of competitive groups, 57.14% of the entries exhibit OH···CONH2
while 55.95% exhibit OH···NH2CO supramolecular heterosynthons. In absence of
competitive functional groups, the percentages increase to 92.59% and 90.74%, for
OH···CONH2 and OH··· NH2CO, respectively. The histogram for bond distance range is
shown in figure 2.36. and it reveals bond distance range of 2.607-2.997Å (mean =
2.759(6) Å) and 2.737 -3.198 Å (mean = 2.990(6) Å), for OH···CONH2 and OH···
NH2CO, respectively
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Figure 2.33. Histogram for OH···CONH2 (left) and that of OH···NH2CO (right)

Another CSD search for structures with both OH and P=O reveals 368 entries. In
presence of competitive groups, 202 (54.89%) entries exhibit OH···P=O supramolecular
heterosynthons. The percentage increases to 66.67% in absence of competitive functional
groups. The histogram for bond distance range is shown in figure 2.37. and it reveals
bond distance range of 2.429-2.899Å (mean = 2.714(4) Å).

Figure 2.34. Histogram for OH···P=O
Another CSD search reveals 930 entries with both OH and Narom. In presence of
competitive groups, 457 (49.14%) entries exhibit OH···Narom supramolecular
heterosynthons. The percentage increases to 68.63% in absence of competitive functional
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groups. The histogram for bond distance range is shown in figure 2.38. and it reveals
bond distance range of 2.590-3.099Å (mean = 2.821(4) Å).

Figure 2.35. Histogram for OH···Narom

To investigate supramolecular heterosynthons between alcoholic OH and
aldehydes or ketones, carbonyl group is used as a representative for the two later groups.
CSD search reveals 3886 entries with both OH and CO. In presence of competitive
groups, 1694 (43.59%) entries exhibit OH···CO supramolecular heterosynthons. The
percentage increases to 64.86% in absence of competitive functional groups. The
histogram for bond distance range is shown in figure 2.39. and it reveals bond distance
range of 2.413-3.098 Å (mean = 2.825(2) Å).

Figure 2.36. Histogram for OH···CO
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CSD search reveals 18475 entries with alcoholic OH. In presence of competitive
groups, 5184 (28.06%) entries exhibit OH···OH supramolecular homosynthons. The
percentage increases to 78.10% in absence of competitive functional groups. Bond
distance range is found to be 2.510-3.070 Å (mean = 2.780(5) Å).

2.3.3. Experimental
All the chemicals used during the preparation were obtained from commercial
sources and used as received. All crystallization experiments were conducted in an
unmodified atmosphere and the solvents were distilled prior to use.
2.3.3.1. Citric acid- iso-nicotinamide cocrystal (DA005)
38.4 mg (0.200 mmol) of citric acid and 73.2 mg (0.600 mmol) of isonicotinamide were dissolved in 5ml of hot methanol until a clear solution was obtained.
The solution was allowed to slowly evaporate at room temperature and colorless crystals
of DA005 were harvested after one day (yield = 106.8mg, 0.257 mmol, 95.7%). (Melting
point = 148oC).

Figure 2.37. Single crystals of citric acid-iso-nicotinamide cocrystal (DA005)

52

2.3.3.2. Dihydrate of citric acid- iso-nicotinic acid cocrystal (DA02)
76.8mg (0.400 mmol) of citric acid and 49.2mg (0.400 mmol) of iso-nicotinic acid
were dissolved in 5ml of methanol by heating on a hotplate, filtered and allowed to
slowly evaporate at room temperature. Colorless crystals of DA02 were harvested after
one day (yield = 114.5mg, 0.241 mmol, 90.9%). (Melting point = 187oC).

Figure 2.38. Single crystals of citric acid- iso-nicotinic acid dihydrate cocrystal
(DA02)

2.3.4. Results and discussion
2.3.4.1. Citric acid- iso-nicotinamide cocrystal (DA005)
The single crystal x-ray crystal structure of DA005 indicates that molecules of
iso-nicotinamide form hydrogen bonds with molecules of citric acid with a stoichiometry
of 2:1. The asymmetric unit of DA005 contains two crystallographically independent isonicotinamide molecules and a citric acid molecule.

Figure 2.39. The asymmetric unit of DA005
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Each molecule of citric acid is linked to three molecules of iso-nicotinamide,
OHacid···Narom (D = 2.521(3) Å) NHamide···COacid (D = 2.832(5) and 2.905(5) Å). There is
further an intramolecular hydrogen bonding in citric acid molecules, OHacid···OHalcohol (D
= 2.902(2) and 2.937(4) Å).
Two iso-nicotinamide molecules form noncentrosymmetric amide dimer through,
NHamide···COamide (D = 2.894(2) and 2.905(5) Å). Each of the aromatic nitrogen atoms of
iso-nicotinamide are further included in a hydrogen-bond interaction with terminal
carboxylic acid group of a citric acid molecule OHacid···Narom (D = 2.521(3) and 2.625(2)
Å) to form zigzag tapes. These tapes are connected through the middle carboxylic acid
moieties of citric acid molecules.

Figure 2.40. Crystal packing in DA005

Based on CSD search discussed earlier, raw search is applicable in this case rather
than refined search because we have four groups which can serve as hydrogen bonding
donors or acceptors. Certainly, there are three functional groups which can act as
hydrogen bonding donors or acceptors; COOH, alcoholic OH, and primary amide. On the
other hand, Narom can act as hydrogen bonding acceptor only.
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However, all interactions reported in DA005 were expected based on CSD search
(raw data), and this can be explained as following: COOH···Narom supramolecular
heterosynthons were observed in 75.29% of entries, COOH···CONH2 were observed in
44.07% of entries, and COOH···OHalc were observed in 42.60% of entries. All observed
hydrogen bonding distances are within the accepted range based on CSD search
discussed in sections 2.3.2.1 and 2.3.2.2.
On the other hand, two supramolecular heterosynthons were not observed while
they have chance to appear based on CSD search. Those are HOOC···OHalc (44.47%),
and OHalc···Narom (49.14%).
In summary, COOH supramolecular heterosynthons were more expected than
COOH···COOH supramolecular homosynthons, and this is the case reported herein.

2.3.4.2. Dihydrate of citric acid- iso-nicotinic acid cocrystal (DA02)
The single crystal x-ray structure analysis of DA02 reveals that the asymmetric
unit contains a dihydrate of 1:2 cocrystal of citric acid and iso-nicotinic acid, where isonicotinic acid molecules are present in zwitterionic form.

Figure 2.41. The asymmetric unit of DA02
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Each molecule of citric acid is linked to two molecules of iso-nicotinic acid,
OHacid···CO and OHalcohol ···CO (D = 2.641(2) and 2.645(2) Å respectively). The
indicated molecule of citric acid is further linked to three water molecules,
OHacid···OHwater (D = 2.556(2) and 2.621(2) Å), OHalcohol···OHwater (D = 2.676(2) Å), and
OHwater···COacid (D = 2.991(2) Å). The two zwitterions of iso-nicotinic acid molecules
constitute molecular tapes through the formation of charge assisted NH+···CO
supramolecular heterosynthons (D = 2.668(2) and 2.676(2) Å). Such tapes are running in
anti-parallel fashion and are connected by two water molecules, OHwater···CO (D =
2.683(2) and 2.740(2) Å) and OHwater···OHwater (D = 2.707(3) Å). The citric acid
molecules connect such anti-parallel tapes through hydroxyl and carboxylic acid moieties
forming sheets.

Figure 2.42. Crystal packing in DA02
This zwitterionic structure is based on charge-assisted hydrogen bonding rather
than neutral hydrogen bonding interactions. This makes it a unique structure and thus,
CSD search discussed earlier is not applicable to this case. It is known that charge56

assisted hydrogen bonding interactions are stronger than neutral hydrogen bonding
interactions, which make distances shorter in the earlier case than the latter one. Thus,
CO- is stronger than neutral CO and this explains dominance of charge-assisted hydrogen
bonding over neutral hydrogen bonding in this crystal structure.
Furthermore, water molecules are able to act as hydrogen bonding donors or
acceptors. Hence, they played important rule in sustaining the crystal structure as they
involved in four out of eight of the hydrogen bonding interactions exhibited herein.
To confirm that iso-nicotinic acid molecules in DA02 are zwitterions, further
study of the crystal structure has to be performed. In addition to IR spectroscopy, two
measurements can be used for this purpose, C-O distances and C-N-C angles of
pyridines.61 -66

Figure 2.43. Comparison of the C-N-C angle of the pyridine and the C-O distances
of the carboxylic acid Moieties in DA02 molecules (left) and iso-nicotinic acid (right)

It is known that in neutral carboxylic acid, C-O distance is longer than that of
C=O. In case of carboxylate, no C=O is present, and thus the distance of both C-O
moieties are in between those of C-O and C=O. Moreover, C-N-C angle is larger in
protonated pyridine than those of neutral ones.
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Table 2.5. Comparison of the C-N-C angle of the pyridine and the C-O distances of
the carboxylic acid Moieties in DA02 molecules (left) and iso-nicotinic acid (right)
Analyzed crystallographic
parameter

Zwitterionic molecules

Iso-nicotinic acid
molecule

C-O distances

1.260 Å, 1.270 Å, 1.244 Å,
1.236 Å

1.215 Å, 1.294 Å

C-N-C angles

121.91°, 121.81°

118.91°

Furthermore, ΔpKa [pKa(base)-pKa (acid)] is traditionally used in pharmaceutical
industry as an indicator of salt formation. It is known that ΔpKa >3 is usually associated
with salt formation67, If the value of ΔpKa is between 2 and 3, formation of either a salt
or a cocrystal cannot be predicted. However, ΔpKa for citric acid and pyridyl moiety of
iso-nicotinic acid = 4.88-2.93= 1.95 which does not meet that criterion for salt formation.
However, it is clear that iso-nicotinic acid molecule has both acidic and basic moieties.
Thus, it might tend to present as zwitterion. Moreover, we can also consider presence of
COOH and Narom in para position as a factor which might stabilize the zwitterions in this
structure.
However, CSD search for iso-nicotinic acid reveals one neutral crystal structure
and there are no cocrystals of iso-nicotinic acid. Thus, no more information about isonicotinic acid cocrystals can be obtained.
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2.4.1. Experimental
112 mg (0.499 mmol) of flavanone were dissolved in 5ml of acetone and heated
on a hotplate. The solution allowed to slowly evaporating at room temperature.

2.4.2. Result and discussion
The crystal structure of flavanone is monoclinic with one molecule of flavanone
in the asymmetric unit.

Figure 2.45. The asymmetric unit of flavanone

The crystal structure does not show strong hydrogen bonding since flavanone
does not have strong hydrogen bond donors, although some forms of weak hydrogen
bonding were observed, CH···CO (D = 3.437 and 3.476 Å) and CH···O (D = 3.475 Å).
The structure sustained by CH-π interactions, CH···centroid (D = 3.604 and 3.834 Å)
which lead to herringbone pattern as shown in figure 2.49.
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Figure 2.46. Hydrogen bonding in flavanone

Figure 2.47. Herringbone pattern in flavanone

2.4.3. Conclusion
Single crystal of flavanone is reported for first time during an attempt to
cocrystallize trans-resveratrol and flavanone. In the crystal structure, weak hydrogen
bond interactions, CH···CO, CH···O and electrostatic CH-π interactions are observed.
Flavanone could be considered as relatively safe; LD50 is 75 mg/kg (bird-wild
bird species), therefore, it can be used as a cocrystal former.
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Chapter 3. Polymorphism

3.1. Introduction
The term Polymorphism (Greek: poly = many, morph = form) was first introduced
around 1822 by Mitscherlich68, while the earliest report of the phenomenon is most
probably found in the works of Klaproth (1788). Klaproth reported two different phases
of calcium carbonate, calcite and aragonite. The phenomenon, for molecules and
complexes, is closely related to allotropism, in elements, where different structural forms
of the same element can exhibit quite different physical properties. Allotropism is best
exemplified by diamond, graphite, and fullerenes, three allotropes of carbon, Figure 3.1.

Figure 3.1. Allotropes of carbon diamond (left), graphite (middle), and fullerene
(right).
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The stunning case of highest number of polymorphs is the case of ROY69,70 [5Methyl-2-[(2-nitrophenyl) amino]-3-thiophenecarbonitrile]. It named ROY because the
crystal colors of its polymorphs are red, orange, and yellow. ROY which has eight
polymorphs and it is an ideal example of conformational polymorphism as discussed in
section 3.1.3.

Figure 3.2. The molecular structure of a red polymorph of ROY (CSD refcode:
CAXMEH03)

A polymorph is defined by McCrone (1965) as “a solid crystalline phase of a
given compound resulting from the possibility of at least two different arrangements of
the molecules of that compound in the solid state”.71
While this definition might imply that structures where molecules exhibit
different conformations are not considered polymorphs, McCrone pointed out that
polymorphs will be essentially the same in liquid and vapor states but different in crystal
structure.72 However, this later “safe” definition of polymorphs can accommodate
conformational polymorphs.
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As the number of published crystal structures has grown exponentially since the
original works of Klaproth, the number of polymorphs has also increased. According to
McCrone, all compounds are polymorphic, and the number of known polymorphs of a
single compound is proportional to time and effort spent researching this compound.71
Other terms related to polymorphism are commonly used in literature. One of
these terms is “pseudopolymorphism”, which is used to describe solvates and hydrates.
The use of this term was a matter of a recent scientific debate. Rogers70, Seddon73, and
Bernstein74 opposed its use on the basis of being a misleading and an ambiguous term
where they recommended journal editors to eliminate it from current usage. However,
Desiraju69,75 argued that despite its ambiguity it has to be retained because it is too
common and it has a scientific value. Nangia76 also agrees on retaining its usage as it is
clear enough to all scientists and he pointed out its scientific and legal importance.

3.1.1. Significance of polymorphism to pharmaceutical industry
Polymorphism has significant applications in pharmaceutical industry. The choice
of the right polymorph is critical during formulation of pharmaceutical preparations.77 As
we pointed out earlier, polymorphs exhibit significantly different physical properties, it is
widely recognized that different polymorphic forms of the same active pharmaceutical
ingredient (API) exhibit different stabilities, solubilitis, melting points, processabilities,
bioavailabilities, particle flow, etc.77 Therefore, it becomes evident that physical
properties of APIs can be optimized through control, and further design, of suitable
polymorphs. A striking example for this phenomenon is demonstrated in the case of
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paracetamol. Two polymorphs of paracetamol form I50 and II (Haisa 1974), reported by
Haisa et al., figure 3.3., exhibit widely different compressibility. This difference in
compressibility greatly affects processing of the drug, and thus represents a good
example of the effect of polymorphism on targeted physical properties in API
formulation. The difference in compressibility between the two polymorphs could
directly be linked to the difference in the underlying packing patterns in the two
polymorphs. In polymorph I, hydrogen-bonded paracetamol molecules crystallize in
puckered hydrogen-bonded sheets, resisting compressibility as the sheets do not slip
easily over each other. On the other hand, paracetamol molecules in form II exhibit flat
sheets that can slip easily over each other, and thus demonstrate better compressibility.

Figure 3.3. Paracetamol polymorphs, (left) form I showing puckered hydrogenbonded sheets, and (right) form II showing flat sheets. (CSD refcodes: HXACAN01
and HXACAN08, respectively)

Effect of polymorphism on bioavailability can be demonstrated by the case of
chloramphenicol palmitate. Chloramphenicol is an antimicrobial agent which has a strong
bitter taste and therefore it cannot be administered orally. Edgerton78 has synthesized a
tasteless chloramphenicol palmitate which is a poorly soluble ester. It does not dissolve in
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mouth while administered orally and it undergoes hydrolysis in the small intestine to
form active chloramphenicol. The rate of ester hydrolysis, which is the rate of absorption
determinant factor, depends on the selection of the right polymorph79 as chloramphenicol
palmitate exhibits polymorphism80-82
Aguiar et al.96 carried out an experiment to study the absorption of two
polymorphs of chloramphenicol palmitate A and B. Varied concentrations of A and B
were administered orally by human volunteers and urine and blood samples were
collected over a 24 hr period. Urinary excretion data are shown in Figure 3.4. which
demonstrate that concentration of chloramphenicol equivalent increases as concentration
of form B increases. Blood concentrations of free chloramphenicol were also plotted
versus percent concentration of form B. This shows that chloramphenicol blood serum
levels proportionally increases by increasing concentration of polymorph B and this
linear relationship is shown in figure 3.5. This study reveals that API absorption is
directly related to the type and concentration of the polymorph.

Figure 3.4. Chloramphenicol urinary excretion rates after oral administer of
chloramphenicol palmitate with varying percents of polymorph B: M, 0%; N, 25%;
O, 50%; P, 75%; and L, 100%96
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Figure 3.5. Blood serum levels of chloramphenicol after oral administer of
chloramphenicol palmitate with varying percents of polymorph B96

One important aspect of polymorphism in pharmaceuticals is susceptibility of
polymorphs to interconvert77, where many consequences can result from conversion of
the kinetically favored form to the thermodynamically stable form either during the
manufacturing processes or upon storage (shelf life). This may result in precipitation of
the low solubility stable form which may lead to pharmaceutically unacceptable
preparations. Consequently, interconversion into the low solubility, thermodynamically
stable, form may limit pharmacological utility of the API77. Furthermore, as the solubility
of API is greatly affected by particle size, precipitation and subsequent particle growth
may lead to variations in particle size distribution in a given formulation, which
subsequently affect the solubility of an active ingredient.
In their review, Haleblian and McCrone72 provided many examples for the
consequences of phase interconversion in pharmaceutical industry. Considering
parenteral preparations, precipitation may result in significant particle growth which may
affect the syringibility of the product. Precipitation in suspensions might lead to caking,
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which could be significant enough to affect the API uniformity and furthermore might
prevent resuspension by shaking.
Other formulations as creams and suppositories can also significantly be affected
by phase conversion. In those cases, it is essential to determine the solubility of the API
in its vehicle as phase interconversion may result in nucleation which could lead to
pharmaceutically and cosmetically unacceptable preparations.
In case of creams, use of an unsuitable polymorph might lead to phase conversion
and precipitation of a more stable phase. Significant particle growth could arise in the
vehicle yielding grainy particles, which might result in cosmetically unacceptable creams
in which the active ingredient is unevenly distributed.
Some suppository bases are polymorphic and the selection of an appropriate
polymorph could affect the melting characteristics of the preparation. The low melting
phase may become softer or even liquefy during the shelf life. Being very soft may
preclude the ability to administer that dosage form. On the other hand, formulation of
suppositories with a high melting phase could result in a hard product which may not
melt upon administration.72 This position could be demonstrated by Theobroma oil84 as a
suppository base exhibiting polymorphism. The metastable α-form has a melting point of
30°C, while the thermodynamically stable β-form has a higher melting point. Using the
appropriate method of manufacture is essential to permit the crystallization of the more
stable, higher melting point β-form.
From the above discussion, it can be seen that investigation of polymorphism and
selection of the suitable polymorph is critical in pharmaceutical industry. Therefore,
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polymorphism can be seen as an opportunity to tailor tune preparations. Since the
thermodynamically stable form has lower solubility than the metastable form, retaining
the metastable form can improve the efficacy of some pharmaceutical preparations.77

3.1.2. Polymorphism and patents in pharmaceutical industry
As we mentioned previously, polymorphs are different in their crystal structures
and thereby they can vary in their physical properties. Hence, discovery of a new
polymorph of an API can be considered as an opportunity to improve its physical
characteristics. Furthermore, the new form may be considered as a new invention and
thus it might be awarded a patent.
There are three criteria to patent a new entity. It has to be novel, useful and nonobvious. New polymorphic form is novel as it has a distinct solid-state structure. It might
be useful if it provides improved physical properties of a certain API. It is also nonobvious since many efforts to predict new polymorphic crystal structures are not
successful so far. 70
According to the Oxford English Dictionary, patent is defined as “a license to
manufacture, sell, or deal in an article or commodity, to the exclusion of other persons; in
modern times, a grant from the government to a person or persons conferring for a certain
definite time the exclusive privilege of making, using, or selling some new invention”.
This definition implies that the purpose of the patent is to prevent other producers from
making, using or selling the invention covered by the patent, and thereby many legal
consequences can result upon patent infringement.
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During characterization of the later product, it found to have different IR and
XRPD than the earlier product and thus Glaxo concluded that it is a different polymorph
of ranitidine hydrochloride, designated form II.
Given the advantages of form II over form I, Glaxo decided to use form II as the
active ingredient of Zantac®. Appropriate commercial procedure for form II preparation
has been developed86 and new patent application has been filled by Glaxo.
As Zantac® sales reached around $3.5 billion annually by 1991; other
pharmaceutical firms looked forward to take a share of these profits by marketing form I
of Zantac® in 1995, the expiration date of the first patent. Novopharm Ltd. chemists
worked on preparation of form I but they ended with form II. Novopharm claimed that
since form II produced by following the production procedure in the first patent,
therefore, the product was always form II and the second patent is invalid. Thus,
Novopharm sought to market form II and filled an abbreviated new drug application at
the FDA. Novopharm notified Glaxo that the second patent is invalid and therefore Glaxo
sued Novopharm for infringement of the second patent. Glaxo proved by evidence that
following the procedure described in the first patent leading to form I rather than form II
and thus, the court decided that the second patent is valid.
Thereafter, Novopharm worked faithfully and succeeded in producing form I of
ranitidine hydrochloride, and filled an abbreviated new drug application. Glaxo sued
Novopharm claiming that the product is a mixture of forms I and II, rather than a pure
form I. Novopharm proved that the product is 99% form I with about 1% impurities
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which may include form II and therefore the court allowed Novopharm to market the
product.
From the above discussion it is clear that the consequences of obtaining a new
form of polymorphic drug can go beyond the direct effects on physical properties to be a
source of litigation.

3.1.3. Conformational polymorphism
The term conformational polymorphism was first introduced by Corradini (1973)
to describe the phenomenon in which flexible molecules crystallize in different
conformations. From conformational perspective, organic molecules can be seen as rigid
or flexible. Rigid molecules can adopt packing polymorphism while flexible molecules
might be able to adopt conformational polymorphism. This phenomenon can be
explained in the light of the intramolecular rotation energy about single bonds. Since this
energy is relatively low, 1-3 kcal mol-1 87, molecules with torsional degrees of freedom
can adopt several conformations in solutions88 and thus they might be able to crystallize
in different conformations.
It is also important to notice that the activity of the biological molecules and APIs
depends mainly on their conformations, thus, investigation of different conformational
polymorphs is essential in drug development.88
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Figure 3.7. General scheme shows different types of polymorphs83

3.1.4. Disappearing polymorphs
Bernstein et al.89 used the term “disappearing polymorphs” to describe the
situations when a particular polymorph is no longer obtained. This phenomenon is widely
recorded in literature where it is difficult to reproduce a metastable form after nucleation
of a thermodynamically more stable form.
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The crystallization process composed of formation of nuclei followed by their
growth. The nucleation step is the determinant step in crystallization. One of the
commonly used techniques to induce growth of a certain polymorph is by intentional
seeding. In some cases seeding might happen unintentionally and lead to formation of
undesirable polymorph. This unintentional seeding may result from contamination with
seeds of the more stable form. The area affected by contamination might be small as a
one lab but it can expand to a town, country or in some cases it might lead to “universal
seeding”.89
Since different forms of a polymorphic compound can be produced by variations
in some experimental conditions as temperature and pressure, Jacewicz and Nayler90
argued that disappearing of a polymorph is temporary and that a given form can reappear
by finding the appropriate experimental conditions. They concluded that “Any authentic
crystal form should be capable of being re-prepared, although selection of the right
conditions may require some time and trouble”.90
The phenomenon of disappearing polymorphism can also be explained by
applying Ostwald rule of stages91 which explains how interconvert happens in case of
polymorphism. The rule states that during crystallization of a polymorphic compound,
the least stable form crystallizes first followed by more stable phases. The conversion of
the metastable form to the more stable form occurs step by step to result finally in
crystallization of the most stable form.
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3.3. Results and Discussion
3.3.1. Salicylamide polymorph II (DA008)
Salicylamide [2-hydroxybenzamide] is an active ingredient in BC Powder®,
which is over-the-counter pain relief product.92 The CSD search shows one crystal
structure of salicylamide (SALMID) with no polymorphic structures. However the
presence of the dihedral angle of the amide-benzene ring planes suggests that
polymorphism of salicylamide may occur.
The crystals of DA008 were obtained during an attempt to prepare a cocrystal of
riboflavin and salicylamide using methanol as a solvent. The crystal structure of DA008
consists of two crystallographically-independent molecules of salicylamide in the
asymmetric unit. The two molecules differ mainly in the dihedral angle of the amidebenzene ring planes, 15.90o and 2.51o, in molecules A and B, respectively. The two
molecules form noncentrosymmetric amide dimers with bond distances (NH2···CO) of
2.867(6) and 2.910(6) Å. The amide molecules do not form catemers because the amide
carbonyl is involved in intramolecular hydrogen bonding with the phenolic OH,
OHa···COa (D = 2.511(5) Å) and OHb···COb (D = 2.497(5) Å), while the amide amine is
involved in intermolecular hydrogen bonding with the neighbor phenolic OH, OHa···NH2a
(D = 2.891(6) Å).Chains of salicylamide molecules result from phenolic OH and amide
NH2 (D = 2.891(6) Å) intermolecular H-bond interactions of molecules A.
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Figure 3.11. Comparison of the dihedral angle in DA008 molecules A and B (left)
with that of SALMID (right)

The structure shows sheets formed by amide dimers of molecules A and B.
Molecules of A are further linked where π-π stacking occurs between the aromatic rings
(face-to-face interactions) with interplanar distance of 3.480 Å. Further interactions
towards neighboring sheets occur through CH-π interactions between molecules A and B,
CHa···centroidb (D= 3.781 Å). Molecules B are further connected to molecules B in the
other sheets through CHb···COb with a distance of 3.267 Å. The overall hydrogen bonding
results in sandwich herringbone pattern as represented in Figure 3.13.
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Figure 3.12. Comparison of hydrogen bonding in DA008 (up) to that in SALMID
(down)

The crystal structure of SALMID is monoclinic with one molecule of
salicylamide in the asymmetric unit. The dihedral angle of the amide-benzene ring planes
is 4.62°. The salicylamide molecules form centrosymmetric amide dimers with bond
distances (NH2···CO) of 2.940 Å. The amide molecules do not form catemers because the
amide carbonyl is involved in intramolecular hydrogen bonding with the phenolic OH,
OH···CO (D = 2.492 Å), while the amide amine is involved in intermolecular hydrogen
bonding with the neighbor phenolic OH, OH···NH2 (D = 2.812 Å). Chains of
salicylamide molecules result from phenolic OH and amide NH2 (D = 2.812 Å)
intermolecular H-bond interactions of salicylamide molecules. The sheets are linked
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through CH-π stacking, CH···centroid (D = 3.721 Å) and through π -π stacking with
interplanar distances of 3.261 and 3.346 Å. The overall hydrogen bonding results in
herringbone pattern as shown in figure 3.16.

Figure 3.13. Illustration of the sandwich herringbone pattern in DA008 (left) and
the herringbone pattern in SALMID (right)

Figure 3.14. Illustration of face to face interactions in DA008 (left) and that in
SALMID (right)

The CSD search shows that 16.32% (39/239) of primary aromatic amide
structures are polymorphic. This polymorphism originates mainly from their flexibility
due to the dihedral angle of the amide-aromatic ring planes. Since polymorphism in most
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of these cases result from variation in conformation rather than the packing, those
structures exhibit conformational polymorphism. The histogram shown in figure 3.15
reveals the dihedral angle of polymorphs of primary aromatic amides and it shows 32
structures with minimum of 0.681°, maximum of 75.833°, and the mean is 24.944°.
Furthermore, The CSD search for the dihedral angle of primary aromatic amides shows
228 structures with minimum of 0.034 and maximum of 86.334°, while the mean is
21.536°. The histogram of the dihedral angle is shown in figure 3.16. The dihedral angles
of molecule B in DA008 and that of SALMID are within the range of majority of the
CSD entries, while that of molecule A in DA008 does not locate in the average value.
However, the dihedral angle of molecule A of DA008 is still has accepted value.

Figure 3.15. Histogram for the dihedral angle of polymorphs of primary aromatic
amides
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Figure 3.16. Histogram for the dihedral angle of primary aromatic amides

As mentioned earlier, the CSD search reveals 239 crystal structures with primary
aromatic amides. 144 entries (60.25%) exhibit amide dimers with bond range of 2.7053.189 Å (mean 2.927 Å). Amide catemers were observed in 177 entries (74.06%) with
bond range of 2.596-3.242 Å (mean 2.940 Å). The histograms are shown in figures 3.17.
and 3.18., respectively. This indicates that amide catemers are more dominant than amide
dimers in primary aromatic amides. However, no amide catemers were observed in any
of the two polymorphs because the amide carbonyl is involved in intramolecular
hydrogen bonding with the phenolic OH. Hence, there are no available amide moieties to
form catemers.
Further CSD analysis shows 26 structures with both primary aromatic amide and
phenol. Only five structures do not contain any competitive hydrogen bonding donors or
acceptors, namely HXBNZM, HXBNZM01, SALMID, SALMID01, and VIDMAX. The
phenolic OH in all of those structures is bifurcated in hydrogen bonding with amide
moieties forming OH···NH2 and OH···CO supramolecular heterosynthons which is also
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observed in DA008 and SALMID. All hydrogen bonding distances are within the
distance ranges discussed above and that discussed in Chapter 2. concerning phenol
hydrogen bonding interactions.

Figure 3.17. Histogram for primary aromatic amide dimers

Figure 3.18. Histogram for primary aromatic amide catemers

Crystals of DA008 were obtained concomitantly with SALMID crystals, and they
transformed later to SALMID crystals. Efforts to reproduce DA008 crystals resulted in
obtaining crystals of SALMID which indicates that SALMID is the more stable form.
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The difficulty to obtain DA008 crystals may result from contamination by
SALMID seeds. This indicates that SALMID is the thermodynamically favored while
DA008 is the kinetically more favored form according to Ostwald rule of stages.91 This
hypothesis can be supported by the fact that DA008 has the highest Z´ value among the
known structures of salicylamide.93
This case of polymorphism originates from flexibility of salicylamide molecule,
thus, it can be considered as conformational polymorphism. At the same time both
polymorphs adopt different packing, so, it can also be considered as packing
polymorphism.

3.3.2. Iso-nicotinamide polymorph III (DA16712)
Iso-nicotinamide [pyridine-4-carboxamide] is a nicotinamide analogue has shown
that it can enhance the activity of antitumor drug, 2-amino-l,3,4-thiadiazole.94
The CSD search shows two polymorphs of iso-nicotinamide (CSD refcodes:
EHOWIH01 and EHOWIH02). Both structures are monoclinic and they differ in the
dihedral angle of the amide-benzene ring planes, the number of molecules in the
asymmetric unit and in their hydrogen bonding patterns.
The crystals of DA16712 were obtained during attempts to prepare cocrystal of
trans-resveratrol and iso-nicotinamide using ethyl acetate as a solvent. The crystal
structure of DA16712 is orthorhombic with one molecule of iso-nicotinamide in the
asymmetric unit. The dihedral angle of the amide-benzene ring planes is 31.75°. The isonicotinamide molecules are extended through amide catemers with bond distances
(NH2···CO) of 3.031(3) Å. The iso-nicotinamide molecules are further forming head to
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tail chains through amide NH2···Narom (D = 2.995(3) Å). The overall structure shows
herringbone pattern sustained by CH-π interactions, CH···centroid (D = 3.664 Å).

Figure 3.19. Comparison of the dihedral angle in DA16712 (left), EHOWIH01
(middle), and molecules A and B in EHOWIH02 (right)

Crystals of EHOWIH01 were prepared by recrystallization of iso-nicotinamide
from methanol, nitrobenzene or nitromethane.95 The crystal structure of EHOWIH01 is
monoclinic with one molecule of iso-nicotinamide in the asymmetric unit. The dihedral
angle of the amide-benzene ring planes is 32.41°. The iso-nicotinamide molecules form
centrosymmetric amide dimers with bond distances (NH2···CO) of 2.9366(16) Å. The
amide molecules are further extended through amide catemers with bond distances
(NH2···CO) of 2.9354(14) Å. The iso-nicotinamide molecules form extended sheets
sustained by weak hydrogen bonding interactions between aromatic CH and adjacent
aromatic nitrogen, CH···Narom (D = 3.4275(19) and 3.4790(19) Å), and by π -π stacking
with interplanar distances of 3.477Å.
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Figure 3.20. Comparison of hydrogen bonding in DA16712 (up), EHOWIH01
(middle), and in assemblies composed of molecules A and B respectively in
EHOWIH02 (down)

Crystals of EHOWIH02 were prepared by recrystallization of iso-nicotinamide
from different solvents; ethanol, water, THF, dioxane, etc.95 The crystal structure of
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EHOWIH02 is monoclinic with two molecules of iso-nicotinamide in the asymmetric
unit. The two molecules differ mainly in the dihedral angle of the amide-benzene ring
planes, 25.44° and 24.82°, in molecules A and B, respectively. Each of the two molecules
give rise to an independent assembly, each contain the same hydrogen bonding pattern
with subtle variations in bond distances. The iso-nicotinamide molecules are extended
through amide catemers with bond distances NH2a···COa (D = 2.934(2) Å) and
NH2b···COb (D = 2.947(3) Å). The iso-nicotinamide molecules are further forming head to
tail chains through amide amine and aromatic nitrogen, NH2a···Naroma (D = 2.982(3) Å)
and NH2b···Naromb (D = 2.974(3) Å). The overall structure shows herringbone pattern
sustained by CH-π interactions, CHa···centroidb (D = 3.902 Å) and by π -π stacking
between B molecules with interplanar distances of 3.539Å.

Figure 3.21. Illustration of the herringbone pattern in DA16712 (left), sheets of
EHOWIH01 (middle), and the herringbone pattern in EHOWIH02 (right)

In contrast to salicylamide polymorphs, all three polymorphs of iso-nicotinamide
exhibit amide catemers because there is no interference with such hydrogen bonding
pattern. This can be predicted from CSD analysis discussed earlier in section 3.3.1.
However, amide dimers were observed in EHOWIH01 in addition to amide catemers.
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This is also anticipated since occurrence of amide dimers is reported in 60.25% of crystal
structures of primary aromatic amides in CSD.
Further CSD analysis reveals 99 structures with both primary aromatic amide and
aromatic nitrogen. 22 of those structures do not contain any competitive hydrogen
bonding donors or acceptors, and 72.73% (16/22) exhibit amide NH2···Narom
supramolecular heterosynthons. This is in accordance with reported structures of
DA16712 and EHOWIH02. However, this was not the case in EHOWIH01 crystal
structure. Overall, all hydrogen bonding distances and dihedral angles are located within
the expected range based on the CSD search discussed earlier in section 3.3.1.
Efforts to reproduce DA16712 crystals resulted in obtaining crystals of
EHOWIH01 which indicates that EHOWIH01 is more stable form. The difficulty to
obtain DA16712 crystals may result from contamination by EHOWIH01 seeds. This
indicates that EHOWIH01 is the thermodynamically favored while DA16712 is the
kinetically more favored form.
This case of polymorphism originates from flexibility of iso-nicotinamide
molecule, thus, it can be considered as conformational polymorphism. At the same time
all polymorphs adopt different packing, so, it can also be considered as packing
polymorphism.

3.3.3 Trans-resveratrol polymorph II (DA2116)
Trans-resveratrol [trans-3,5,4'-trihydroxystilbene] is a nutraceutical with
antioxidant properties and many promising applications in medicine as discussed in
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section 2.2.1. The CSD search shows one crystal structure of trans-resveratrol
(DALGON) with no polymorphic structures. However the presence of the dihedral angle
of the two aromatic ring planes suggests that polymorphism of trans-resveratrol may
occur.
The crystal structure of DA2116 is monoclinic with two molecules of transresveratrol in the asymmetric unit. The dihedral angles of the two aromatic ring planes
are 8.51° and 2.17°. Each A molecule of trans-resveratrol is hydrogen bonded to other six
molecules of molecules B of trans-resveratrol through supramolecular homosynthons,
OHA···OHB. Two of these molecules are almost on the same plane with the indicated
trans-resveratrol molecule while the other four are aligned perpendicular to that plane.
The bond distances are: OHAa···OHBb (D = 2.668(2) Å), OHAa···OHBc (D = 2.706(2) Å),
OHAb···OHBa (D = 2.710(2) Å), OHAb···OHBb (D = 2.677(2) Å), OHAc···OHBa (D =
2.715(2) Å), and OHAc···OHBc (D = 2.709(2) Å). In the crystal structure, sheets of
molecules A and B, alternatively stacked, with interplanar distance of 3.210 Å are
observed.
The crystal structure of DALGON75 is monoclinic with one molecule of transresveratrol in the asymmetric unit. The dihedral angle of the two aromatic ring planes in
DALGON is 5.33°. Each molecule of trans-resveratrol is hydrogen bonded to other six
molecules of trans-resveratrol through supramolecular homosynthons, OH···OH. Two of
these molecules are almost on the same plane with the indicated trans-resveratrol
molecule while the other four are aligned perpendicular to that plane. The bond distances
are: OHa···OHb (D = 2.685 Å), OHa···OHc (D = 2.687 Å), OHb···OHb (D = 2.727 Å), and
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OHc···OHc (D = 2.754 Å). The molecules are further connected through π-π stacking with
interplanar distance of 3.305 Å.

Figure 3.22. Comparison of hydrogen bonding in DA2116 (left) and that of
DALGON (right)

Figure 3.23. Illustration of the packing in DA2116 (left) and that in DALGON
(right)

From the above discussion, it is clear that both DA2116 and DALGON adopt the
same hydrogen bonding pattern with subtle variations in hydrogen bond distances. All
hydrogen bonding distances are within the expected range based on CSD analysis
discussed in section 2.2.2. However, the presence of OH···OH supramolecular
homosynthon was expected due to the absence of any other moieties which can
participate in hydrogen bonding. Furthermore, CSD search reveals that in absence of any
other competing hydrogen bonding moieties, 59.72% out of 216 entries shows OH···OH
supramolecular homosynthons.
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Since trans-resveratrol is a flexible molecule, both structures differ mainly in their
conformations, and this is an obvious example of conformational polymorphism.

3.3.4. Citric acid monohydrate polymorph II (C-azod)
Citric acid is a nutraceutical with antioxidant properties and many pharmaceutical
and industrial applications as discussed in section 2.3.1. Citric acid can present as
anhydrous [2-hydroxy-1,2,3-propanetricarboxylic acid] or monohydrate [2-hydroxy1,2,3-propanetricarboxylic acid monohydrate]. However, CSD search reveals two
polymorphs of citric acid anhydrate and only one structure of citric acid monohydrate.
We record herein a new polymorph of citric acid monohydrate (C-azod).
The crystal structure of C-azod is triclinic with one molecule of citric acid and
one molecule of water in the asymmetric unit. Each molecule of citric acid forms two
distinct centrosymmetric acid dimers with two citric acid molecules, OH···CO (D =
2.625(5) and 2.645(5) Å). The indicated molecule is hydrogen bonded to two water
molecules, acidic OHacid···OHwater (D = 2.675(5) and 3.035(8) Å), and OHalcohol···OHwater
(D = 3.024(7) Å). There is intramolecular hydrogen bonding between OHalcohol···COacid
(D = 2.903(8) Å). The overall structure shows sheets of citric acid and water molecules
linked to other sheets through the same hydrogen bonding patterns in addition to
OHalcohol···COacid (D = 2.875 Å).
The crystal structure if CITARC is orthorhombic with one molecule of citric acid
and one molecule of water in the asymmetric unit. Trimers formed of two citric acid
molecules with one water molecule were observed, OHacid···COacid (D = 2.755 Å),
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OHacid···OHwater (D = 2.623 Å), and OHwater···COacid (D = 2.761 Å). That water molecule is
further linked to the citric acid molecule in the next layer, OHacid···OHwater (D = 2.695
Å).the alcohol moieties also share in connecting the layers, OHalcohol···COacid (D = 2.765
Å) and OHalcohol··· OHwater (D = 2.768 Å). There is intramolecular hydrogen bonding
between OHacid···COacid (D = 3.020 Å). The overall structure shows sheets of citric acid
and water molecules connected to other sheets through the same hydrogen bonding
patterns.

Figure 3.24. Comparison of hydrogen bonding in C-azod (left) and that of CITARC
(right)

Comparing the two structures, both structures form two dimensional sheets which
extend to form three dimensional structures. But it is obvious that C-azod crystal
structure is mainly controlled by acid dimers, while water molecules are present as guest
molecules. On the other hand, water molecules in CITARC share with two molecules of
citric acid to form trimers. However, based on CSD analysis discussed in section 2.3.2.,
acid dimmer occurs in 31.35% of CSD entries in presence of other competing groups.
Furthermore, OHalcohol···COacid supramolecular heterosynthons is reported in 44.47% of
CSD entries in presence of other competing groups. This supramolecular heterosynthons
92

observed in the two polymorphs of citric acid monohydrate. Moreover, CSD search
reveals 5050 structures of organic hydrates, 43 (0.85%) of those structures exhibit
polymorphism. On the other hand, polymorphism in single component structures is more
common, 1.4% (1882/134,086).
Since the main difference between the two polymorphs is in their packing, this is
considered as a case of packing polymorphism.

3.4. Conclusion
The four cases of polymorphism described in this chapter demonstrate two widely
encountered types of polymorphism, namely conformational and packing polymorphism.
Molecular flexibility in salicylamide, iso-nicotinamide, and trans-resveratrol resulted in
isolation of conformational polymorphs while citric acid monohydrate exhibits packing
polymorphism.
Generally, new polymorphs were obtained by serendipity, but systematic study of
polymorphism can also be performed by varying some factors such as; temperature,
pressure, solvent, and additives.
Polymorphism has a significant importance in industry, in general, and in
pharmaceutical industry, in particular, due to the vast differences in physical properties of
polymorphs. Furthermore, the study of polymorphism provides valuable information
essential to understand how different crystal forms are attained.
Moreover, Aakeroy et al.95 argued that polymorphic compounds are considered as
good cocrystal formers since they have synthons flexibility.
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Appendix 1. Experimental data
The experiments were performed using DSC (TA instrument 2920), FT-IR (Nicolet
Avatar 320 FTIR, solid state), X-ray powder diffraction (Bruker AXS D8, Cu radiation),
and TGA (STM6000).

1.1. Experimental Data for DA182901
DSC thermogram, FT-IR spectrum, and X-ray powder diffraction patterns of bulk sample
(down) and calculated from the single crystal structure (up).
Sample: DA1829
Size: 4.2000 mg
Method: Ramp

File: C:...\Dalia\DA1829.001
Operator: Dalia
Run Date: 13-Jul-08 23:57
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1.2. Experimental Data for DA182902
DSC thermogram, FT-IR spectrum, X-ray powder diffraction patterns of bulk sample
(down) and calculated from the single crystal structure (up), and TGA.
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1.3. Experimental Data for RESVONE 01
DSC thermogram, FT-IR spectrum, X-ray powder diffraction patterns of bulk sample
(down) and calculated from the single crystal structure (up), and TGA.
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1.4. Experimental Data for RESVONE 02
X-ray powder diffraction patterns of bulk sample (down) and calculated from the single
crystal structure (up).

1.5. Experimental Data for DA4
DSC thermogram, FT-IR spectrum, X-ray powder diffraction patterns of bulk sample
(down) and calculated from the single crystal structure (up), and TGA.

106

96
94

2357.62

92

88

2587.24

3003.68

90

86

1582.83

74
72
70

998.78

1209.18

618.61

76

836.11

78

1169.87

1512.33

80

1406.05
1302.52
1272.93

%T

82

966.66

84

66
64
4000

3000

2000

1000

799.02

68

cm-1

1.0

Relative intensity

0.8

0.6

0.4

Calculated (2
0.2

Experimental

0.0

0

5

10

15

20

25

2θ

0

107

30

35

40

45

1.6. Experim
mental Data for DA005
D thermog
DSC
gram, FT-IR
R spectrum, X-ray
X
powdeer diffractionn patterns off bulk samplee
(ddown) and calculated froom the singlee crystal struucture (up), and
a TGA.
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1.7. Experim
mental Data for DA02
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1.8. Experimental Data for flavanone
DSC thermogram, FT-IR spectrum, X-ray powder diffraction patterns of bulk sample
(down) and calculated from the single crystal structure (up), and TGA.
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1.9. Experimental Data for DA16712
DSC thermogram and X-ray powder diffraction patterns of bulk sample (down) and
calculated from the single crystal structure (up).
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1.10. Experimental Data for DA2116
DSC thermogram, FT-IR spectrum, X-ray powder diffraction patterns of bulk sample
(down) and calculated from the single crystal structure (up), and TGA.
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Appendix 2. Crystallographic data
2.1. Crystallographic data for trans-resveratrol-caprolactam polymorphic cocrystal
(DA182901 and DA182902)
Identification code

DA182902

DA182901

Empirical formula
Formula weight
Temperature

C26 H34 N2 O5
454.55
293(2) K

C26 H34 N2 O5
454.55
100(2) K

Crystal system

Orthorhombic
P n a 21

Triclinic

Space group

a = 12.6665(10) Å, α = 90°
Unit cell dimensions

b = 8.2167(5) Å, β = 90°
c = 22.7749(19) Å, γ = 90°

P -1
a = 8.1803(2) Å, α =
114.627(2)°
b = 13.0557(3) Å, β =
106.532(2)°
c = 13.4915(5) Å, γ =
96.5990(10)°

Volume

2370.3(3) Å3

1209.76(6) Å3

Z, Z`
Final R indices [I>2sigma(I)]
R indices (all data)

4, 1
R1 = 0.0638, wR2 = 0.1471
R1 = 0.0954, wR2 = 0.1729

2, 1
R1 = 0.0403, wR2 = 0.1239
R1 = 0.0427, wR2 = 0.1280
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2.2. Crystallographic data for trans-resveratrol-flavone polymorphic cocrystal
(RESVONE 01 and RESVONE 02)
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system, space
group

RESVONE01
C44 H32 O7
672.70
293(2) K
1.54178 Å

RESVONE02
C44 H32 O7
672.70
293(2) K
1.54178 Å

Monoclinic, P 21

Orthorhombic, P c a 21
a = 12.3620(5) Å, α = 90°

Volume
Z, Z`

a = 7.8768(7) Å, α = 90°
b = 23.796(3) Å, β =
101.380(6)°
c = 9.2317(8) Å, γ = 90°
1696.4(3) Å3
2, 1

Goodness-of-fit on F2

1.004

0.946

Final R indices
[I>2sigma(I)]

R1 = 0.0549, wR2 = 0.1224

R1 = 0.0445, wR2 = 0.0985

Unit cell dimensions

b = 19.0460(5) Å, β = 90°
c = 14.4410(8) Å, γ = 90°
3400.1(2) Å3
4, 1

2.3. Crystallographic data for trans-resveratrol and 4,4'-dipyridyl cocrystal(DA4)
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z, Z`
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]

da4_0m
C58 H48 N6 O6
925.02
298(2) K
1.54178 Å
Triclinic
P-1
a = 9.4975(11) Å, α = 91.319(7)°
b = 10.3208(13) Å, β = 95.689(6)°
c = 26.494(3) Å, γ = 108.619(6)°
2444.8(5) Å3
2, 1
7642 / 0 / 826
1.000
R1 = 0.0691, wR2 = 0.1817
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2.4. Crystallographic data for flavanone single crystal
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z, Z`
Goodness-of-fit on F2
Final R indices
[I>2sigma(I)]

da2720_0m
C15 H12 O2
224.25
293(2) K
1.54178 Å
Monoclinic
P21/n
a = 10.598(5) Å, α = 90°
b = 5.543(3) Å, β = 92.479(10)°
c = 19.105(9) Å, γ = 90°
1121.3(9) Å3
4, 1
0.795
R1 = 0.0470, wR2 = 0.1072

2.5. Crystallographic data for citric acid- iso-nicotinamide cocrystal, DA005 (left)
and that of citric acid- iso-nicotinic acid cocrystal dihydrate, DA02 (right)
Identification code
Empirical formula
Formula weight
Temperature
Crystal system
Space group

Unit cell dimensions

DA005
C18 H20 N4 O9
416.22
178(2) K
Monoclinic
Cc

da02m
C18 H22 N2 O13
474.38
100(2) K
Triclinic
P-1

a = 31.39(2) Å, α = 90°

a = 8.243(3) Å, α =
87.722(7)°

b = 5.319(4) Å, β =
101.243(14)°
1926(2) Å3
4, 1
1.352

b = 10.427(4) Å, β =
87.076(6)°
c = 12.761(5) Å, γ =
70.171(7)°
1030.1(7) Å3
2, 1
0.984

R1 = 0.0830, wR2 = 0.1931

R1 = 0.0438, wR2 = 0.1057

c = 11.762(8) Å, γ = 90°
Volume
Z, Z`
Goodness-of-fit on F2
Final R indices
[I>2sigma(I)]
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Appendix 3. Comparing crystal structures of new polymorphs to that of known
polymorphs
3.1. Comparing crystal structures of salicylamide polymorphs
Salicylamide form I
(SALMID)

Salicylamide form II (DA008)

Dihedral angles

4.62°

15.90o and 2.51o

Hydrogen bonding

Amide dimers (2.940 Å),
Intramolecular hydrogen
bonding (2.492 Å), OH···NH2
(2.812 Å), CH···π stacking
(3.721 Å), π -π stacking
(3.261 and 3.346 Å)

Amide dimers (2.867 and 2.911
Å), Intramolecular hydrogen
bonding (2.512 Å and 2.497 Å),
OH···NH2 (2.891 Å), CH-π
stacking (3.781 Å), CHb···COb
(3.267 Å), π -π stacking (3.480 Å)

Space group

I2/a, monoclinic

P21/n, monoclinic

Z

8

8

Z´
a (Å)
b (Å)
c (Å)
α (°)
β (°)
γ (°)
Volume (A3)

1
12.920
4.980
21.040
90.00
91.80
90.00
1353.08

2
6.483(5)
15.735(11)
12.632(9)
90.00
100.335
90.00
1267.68
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3.2. Comparing crystal structures of iso-nicotinamide polymorphs

Iso-nicotinamide form
I(EHOWIH01)

Iso-nicotinamide form II
(EHOWIH02)

Iso-nicotinamide
form III
(DA16712)

Dihedral angles

32.41°

25.44° and 24.82°

31.75°

Hydrogen bonding

Amide catemers
(2.935 Å), Amide
dimers (2.937 Å),
CH···Narom (3.427 and
3.479 Å), π –π
stacking (3.477Å)

Amide catemers (2.935
and 2.947 Å), NH2···Narom
(2.982 and 2.974 Å), CH-π
interaction (3.902 Å), π –π
stacking (3.539Å)

Amide catemers
(3.031 Å),
NH2···Narom
(2.995 Å), CH-π
stacking (3.664
Å)

Space group

P21/c, monoclinic

P21/c, monoclinic

Pbca,
orthorhombic

Z

4

8

8

Z´

1

2

1

a (Å)
b (Å)
c (Å)
α (°)
β (°)
γ (°)
Volume (A3)

10.1756(11)
5.7319(6)
10.0340(10)
90.00
98.042(7)
90.00
579.483

15.735(3)
7.9976(18)
9.885(3)
90.00
105.586(17)
90.00
1198.21

10.1725(6)
7.4507(6)
15.9013(9)
90.00
90.00
90.00
1205.2
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3.3. Comparing crystal structures of trans-resveratrol polymorphs

Trans-resveratrol form I
(DALGON)

Trans-resveratrol form II
(DA2116)

Dihedral angles

5.33°

8.51° and 2.17°

Hydrogen bonding

OH···OH (2.685, 2.687, 2.727,
and 2.754 Å), π –π stacking
(3.305 Å)

OH···OH (2.668, 2.706,
2.710, 2.677, 2.715, and
2.709 Å), π –π stacking
(3.210 Å)

Space group
Z
Z´
a (Å)
b (Å)
c (Å)
α (°)
β (°)
γ (°)
Volume (A3)

P 21/c, monoclinic
1
4
4.3791(5)
9.2158(11)
26.681(3)
90.00
92.748(2)
90.00
1075.52

P21/n, monoclinic
2
8
8.6551(3)
9.1847(3)
26.6412(9)
90.00
93.090(2)
90.00
2114.75(12)
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3.4. Comparing crystal structures of citric acid monohydrate polymorphs
Identification code

Citric acid monohydrate form I
(CITARC)

Hydrogen bonding

Acid dimers (2.625 and 2.645 Å),
OHacid···OHwater (2.675 and 3.035
Å), OHalcohol···OHwater (3.024 Å),
OHalcohol···COacid (2.903 and 2.875)

Space group
Z
Z´
a (Å)
b (Å)

P 21 21 21, orthorhombic
4
1
6.297(3)
9.319(3)

Citric acid monohydrate form II
(C-azod)
OHacid···COacid (2.755 and 3.020
Å), OHacid···OHwater (2.623 and
2.695 Å), OHwater···COacid (2.761
Å), OHalcohol···COacid (2.765 Å),
OHalcohol··· OHwater (2.768 Å)
P-1, triclinic
2
1
6.781(3)
7.630(4)

c (Å)

15.398(3)

8.788(4)

α (°)
β (°)
γ (°)
Volume (A3)

90
90
90
903.581

93.041(10)
106.201(8)
100.819(10)
426.1(4)
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